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1 Abstract 
1.1 Background 
Ovarian reserve is a key component influencing reproductive function and fertility. Serum anti-
Mullerian hormone (AMH) and the antral follicle count (AFC) are established markers of 
ovarian reserve relevant for routine clinical practice. Additionally, AMH may also have a 
physiological inhibitory role in follicular recruitment and cyclical follicular growth and 
maturation. This may be heightened in polycystic ovary syndrome (PCOS) resulting in 
ovulatory dysfunction. The ovarian reserve is variable and may be affected by genetic, lifestyle 
and environmental factors, in addition to age. However, literature reports contradictory results 
for the effect of cigarette smoking on ovarian reserve parameters. As the antral follicle pool is 
a dynamic cohort of growing follicles it is responsive to the action of gonadotropins, ovarian 
steroids and other endocrine and paracrine influences. Hence there is biological plausibility to 
alter folliculogenesis with pharmacological agents acting through one of these pathways. In the 
context of in-vitro fertilisation (IVF), serum AMH and AFC are commonly used to estimate 
the quantitative response to controlled ovarian hyperstimulation. Their association with 
embryo quality is less well established and inconclusive. 
1.2 Objectives 
The overall aim of this thesis was to study the role of AMH and AFC on different aspects of 
fertility and fertility treatment. The thesis comprised of four work packages. Their specific 
objectives were: 
1) To compare the per follicle AMH production (expressed as a ratio of serum AMH to 
the total AFC) in the various phenotypes of women with PCOS and with isolated 
polycystic ovarian morphology (PCOM). We also aimed to evaluate the factors which 
may be associated with variation in AMH production among these different clinical 
phenotypes. 
2) To assess the effect of cigarette smoking on the quantitative ovarian reserve parameters 
in sub-fertile women, validating self-reported smoking behavior using biomarkers 
(breath carbon monoxide levels and urine cotinine levels). 
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3) To assess the effect of treatment with myo-inositol (MI)/di-chiro inositol (DCI) 
compared to no treatment, placebo or other treatment on markers of ovarian reserve in 
women with PCOS combining data from published literature. Our secondary aim was 
to assess the effect of these treatments on reproductive outcomes in women with PCOS 
undergoing IVF/ intracytoplasmic sperm injection (ICSI) treatment. 
4) To assess the association between ovarian reserve markers and embryo quality in 
women undergoing IVF/ICSI treatment using time lapse imaging technology.  
1.3 Methods 
The work for the thesis included primary research and evidence synthesis. Our primary 
research comprised of three single-centre observational cross-sectional studies using a 
population of subfertile women seeking fertility treatment. For Paper I we measured serum 
AMH and total AFC in women with PCOS and PCOM. We calculated a ratio of serum AMH 
to the total AFC as a marker of AMH production per follicle and compared this in the different 
phenotypes of PCOS and PCOM. We also compared the secondary outcome measures, i.e. free 
androgen index (FAI), homeostatic model assessment (HOMA) and serum luteinising hormone 
(LH), in the comparison groups. For Paper II, we compared serum AMH and AFC in current 
smokers, ex-smokers and never smokers. We assessed smoking exposure using a self-reported 
questionnaire. We also measured biomarkers of smoking using a carbon monoxide (CO) breath 
test and a urine cotinine test. We compared these biomarkers between the groups to validate 
the results for the primary outcome variables and also evaluated the association between 
biomarkers of smoking and biomarkers of ovarian reserve. The pack years of smoking were 
compared between current smokers and ex-smokers and their correlation to serum AMH and 
total AFC was assessed. For Paper III, we conducted a systematic review and meta-analysis 
using standard methodology recommended by Cochrane to study the effect of the insulin 
sensitiser MI/DCI on serum AMH and AFC in women with PCOS undergoing IVF/ICSI. For 
Paper IV, we measured baseline serum AMH and assessed embryo quality using the time lapse 
incubators and a computerised known implantation data score (KID score) in women 
undergoing IVF/ICSI treatment. We compared serum AMH in the five KID score categories. 
We also compared the clinical pregnancy rate in the five KID score categories and explored 
the relative impact of serum AMH and the number of retrieved oocytes on the pregnancy rate. 
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1.4 Results 
Per follicle AMH production was significantly higher in the anovulatory phenotypes of PCOS 
as compared to the ovulatory phenotypes and isolated PCOM. There was no substantial 
association between the per follicle AMH production and androgens, LH or insulin. No 
significant differences in serum AMH or AFC were found between current smokers, ex-
smokers and never smokers. There was a good correlation between self-reported smoking 
history and biomarkers of smoking. No significant correlation between biomarkers of smoking 
or lifetime exposure to smoking and ovarian reserve parameters was found. There was no 
consistent direction or size of effect for a change in serum AMH or AFC after treatment with 
inositols. No significant differences between the inositol and control groups were seen for the 
number of retrieved oocytes, number of metaphase II oocytes, number of top-grade embryos, 
pregnancy rates and the rates of cycle cancellation due to the risk of OHSS in women 
undergoing IVF/ICSI treatment. The serum AMH levels were similar in women with different 
categories of embryo quality, although there was a significant difference in pregnancy rate 
between the KID score categories. Serum AMH however did not have a significant impact on 
pregnancy rates.  
1.5 Conclusions 
A greater per follicle AMH production in anovulatory phenotypes of PCOS may represent a 
heightened physiological role of AMH leading to ovulatory dysfunction. Exposure to cigarette 
smoking in women £ 35 years seeking fertility treatment did not significantly change the antral 
follicle pool and the biomarkers of ovarian reserve were not significantly associated with the 
biomarkers of smoking or lifetime smoking exposure. 
Based on currently available data, evidence is lacking for an effect of inositols on altering 
ovarian reserve markers or subsequent outcomes following IVF/ICSI treatment. We found no 
significant association between ovarian reserve markers and embryo quality in women 
undergoing IVF/ICSI treatment. Their positive association with improved pregnancy outcomes 
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3 Introduction 
3.1 Ovarian development 
The first anatomical description of the ovary can be credited to the Greek physician Soranus 
(98-138 AD). However, it was several centuries later that Fabricius (1533-1619), the chair of 
anatomy at Padua University, named the structure that contained eggs as the ovary. The origin 
of the word ovary is from the Greek word ‘ovum’ meaning egg. In 1672 the Dutch physician, 
Reinier de Graaf established the ovary as the source of the ovum in his work “A new treatise 
on the Female Reproductive Organs”. His work earned him great recognition and the ovarian 
follicle is named after him as the Graafian follicle. 
The female germ cells are ectodermal in origin and are present at the base of the yolk sac 
following fertilization (1). These germ cells migrate towards the genital ridges between 4-6 
weeks of gestation to form the gonads (2). Besides the germ cells the gonad also contains 
somatic cells. The germ cells proliferate during migration and in the female fetus differentiate 
into oogonia directed by the sex chromosomes. There is a phase of rapid mitotic division of the 
germ cells between 6-8 weeks of gestation taking the final number of oogonia to 6-7 million 
by 16-20 weeks of gestation. From about 11-12 weeks of gestation, oogonia containing 46 
chromosomes, are transformed to oocytes with 23 chromosomes, by the first meiotic division 
and arrest in prophase (3). At approximately 18-20 weeks when the ovarian cortex is 
vascularised, the process of follicle formation begins. Cells from the coelomic epithelium 
surround the oocyte to form the primordial follicle. The primordial follicles can then mature 
through various phases to develop in to primary, pre-antral and antral follicles. Germ cell loss 
takes place throughout this process of mitosis and meiosis resulting in a final number of about 
500,000- 2 million germ cells/primordial follicles at birth (2, 4). Ovarian structure may be 
broadly divided in to the cortex and medulla with the cortex containing the primordial follicles. 
During childhood, despite low levels of gonadotropins, the ovary is not quiescent and follicular 
recruitment and growth from the primordial to the antral follicular stage continues. In adult life 
following puberty, under the influence of gonadotropins, antral follicles continue to follow a 
cycle of follicular maturation, selection for dominance and ovulation. An ongoing process of 
follicular atresia continues alongside these processes and contributes to the steady decline in 
oocyte numbers until the age of menopause.  
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3.2 Ovarian reserve markers 
As detailed above, the human ovary establishes its full complement of primordial follicles in 
fetal life (2) which decreases over the reproductive lifespan up to menopause, at the average 
age of 51 years (5). This complete and non-renewable complement of primordial follicles 
comprises the true ovarian reserve and is the key determinant of the function and lifespan of 
the ovary. There is no currently known biochemical marker for estimation of the number of 
primordial follicles and their small size makes resolution for in-vivo imaging impossible.  
Hence, estimation of the size of the primordial follicle pool is difficult and impractical for 
routine clinical application. Primordial follicles are continuously recruited into a smaller cohort 
of growing follicles called the antral follicle pool (6). Antral follicles are sensitive to the actions 
of gonadotropins (7) and during the adult reproductive lifespan, are involved in cyclical 
follicular recruitment, selection of the dominant follicle and ovulation. Hence it is relevant to 
estimate the size of this pool of non-dormant follicles for clinical practice. Several biochemical 
and ultrasound markers and challenge tests have been developed to estimate the size of the 
antral follicle pool. These include serum AMH, AFC, basal serum follicle stimulating hormone 
(FSH) and basal serum inhibin.  
The granulosa cells of the primary, secondary, pre-antral and small antral follicles secrete 
AMH  (8). As AMH is secreted exclusively by the granulosa cells in the ovary, its measurement 
provides a direct quantitative reflection of the antral follicle pool. Literature reporting the 
influence of sex steroids on AMH expression and circulating AMH is contradictory (9-11). 
Serum AMH levels measured on day 3 of the menstrual cycle progressively decrease with age 
and are not detected after menopause(12). Serum AMH levels also show an excellent 
correlation with the number of retrieved oocytes during IVF treatment (9, 13). These indicate 
serum AMH to be a good marker of the antral follicle pool.  
The antral follicle pool may also be estimated by in-vivo ultrasound measured AFC. AMH and 
AFC show an excellent correlation with each other as they measure the same biological entity 
(9). These ovarian reserve markers, representing the size of the antral follicle pool, have 
demonstrated a good correlation with the size of the primordial follicle pool in adult women 
(14). Hansen et al (2011), evaluated the relationship between ovarian reserve markers and 
primordial follicle counts assessed histologically. 42 women between 26-52 years were 
recruited to the study. After correcting for chronological age, serum AMH and AFC 
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significantly correlated with the primordial follicle count (r = 0.48 and r = 0.53 respectively) 
(14). Other studies using indirect methods have supported these findings. Observational data 
have demonstrated association between poor response to assisted reproduction treatments and 
early menopause (15) and prospective changes in ovarian reserve markers and age at 
menopause (16, 17). Hence AMH and AFC may be considered suitable indirect markers of 
ovarian reserve for clinical application in the adult female population.  
Basal serum FSH is an indicator of pituitary function and may be considered relevant as an 
indirect marker of ovarian function in women of reproductive age with regular menstrual 
cycles. It is an inappropriate indicator of ovarian function in childhood and adolescence, states 
of pituitary suppression such as hypothalamic amenorrhoea or pituitary suppression due to long 
term treatment with oral contraceptive pills (OCP) or gonadotropin releasing hormone (GnRH) 
analogues. Serum FSH levels also show considerable inter-cycle and intra-cycle variability 
which make it less suitable as a test for ovarian reserve (18). Basal serum FSH has been used 
to estimate ovarian response and predict poor response to exogenous gonadotropins in the 
context of assisted reproduction treatment. In a systematic review, Broekmans et al (2006), 
reviewed 37 studies reporting the use of FSH to assess ovarian response to in-vitro fertilisation 
(IVF).  They concluded that serum FSH did not show good clinical value as it could accurately 
predict a poor response only at very high values and there was a very low number of such 
abnormal tests reported (19). Fanchin et al (2003), investigated the correlation between the 
AFC on day 3 and other hormonal markers of ovarian reserve (9). Serum FSH levels showed 
only a weak correlation with the AFC (r=0.29, p<0.001) as compared to serum AMH (r=0.74, 
p<0.0001).  
Serum inhibin may be considered a direct indicator of ovarian reserve as it is produced by the 
granulosa cells. Serum inhibin levels are however influenced by FSH stimulation with an 
increase in serum inhibin observed with increasing FSH levels in the follicular phase of the 
cycle (20). Serum inhibin levels also showed only a weak correlation with the AFC (9).  
Hence for the purpose of this thesis we have included only serum AMH and AFC as markers 
of ovarian reserve for investigation. 
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3.3 Physiological role of AMH 
AMH is produced in females exclusively by the granulosa cells of the ovary (21). Although its 
exact role is not clearly understood, an inhibitory role for ovarian folliculogenesis, and also for 
cyclical follicular maturation and ovulation has been hypothesised.  
The exact mechanisms for the progression of follicles from the primordial to the antral follicle 
pool remain unknown. It has been proposed that the primordial follicles remain dormant due 
to a constant inhibitory influence (22). Movement to the growing or antral follicle pool may be 
due to removal of the inhibitory influence or presence of a stimulatory influence. Functional 
gonadotropin receptors have not been demonstrated in primordial follicles and hence it is 
unlikely that gonadotropins may influence the initial primordial follicle recruitment (23).The 
early growth of primordial follicles is independent of gonadotropins and is thought to be 
influenced by AMH. In-vitro studies on AMH null mice demonstrated a smaller number of 
primordial follicles and greater number of antral follicles as compared to control mice (24). 
Also, in-vitro treatment of neonatal mouse ovaries with exogenous AMH showed an inhibitory 
effect on the size of the antral follicle pool (25). This led to the hypothesis that AMH may have 
an inhibitory effect through the action of local paracrine factors on initiation of follicular 
growth in primordial follicles. This led to investigation of AMH expression in human ovaries. 
Weenen et al (2004), studied sections of human oophorectomy specimens by 
immunohistochemical staining for AMH. AMH expression was observed from the primary 
follicle stage, was maximal in the pre antral and small antral follicles and declined in larger 
antral follicles (8). AMH was not expressed by primordial follicles (8).  AMH expression has 
been detected as early as 36 weeks of fetal life (26) and continues till the menopause. Stubbs 
et al (2008), in a study similar to Weenen et al (2004), confirmed their findings (27). This study 
also demonstrated AMH expression in some primordial follicles although the authors confirm 
that this was less prevalent and of lower intensity. This pattern of immunohistochemical 
staining and AMH expression in humans supports the animal model hypothesis for the 
inhibitory role for AMH in initial recruitment and early folliculogenesis. 
AMH also plays an important role in cyclical follicular maturation for follicles in the antral 
follicle pool. In pre antral and small antral follicles, AMH inhibits FSH induced aromatase 
which promotes the conversion of androgens to estrogens. Pellatt et al (2007), measured AMH 
levels in follicular fluid and granulosa cells in antral follicles measuring between 2-10 mm 
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from normal ovaries. The concentration of AMH in follicular fluid and granulosa cells was 
high in small antral follicles, with maximum concentrations observed in follicles between 3-5 
mm (28). An exponential decrease in AMH levels was observed with increasing follicular size. 
AMH levels were at the lowest level of detection (0.025 ng/ml) or undetectable in follicles 
greater than or equal to 10 mm (28). Similar findings were reported by Andersen et al (2010), 
where follicular fluid concentrations of AMH progressively decreased from a size of 3 mm to 
9 mm (29). In-vitro treatment of rat granulosa cells with AMH resulted in reduced aromatase 
activity (30). Similar results were seen on studies involving human granulosa cells (31). These 
findings support the hypothesis for the inhibitory role of AMH in antral follicles and its 
subsequent decrease with increasing follicular size and selection of the dominant follicle.   
3.4 Role of AMH in ovulatory dysfunction 
Polycystic ovary syndrome (PCOS) is the commonest endocrinological disorder in women of 
reproductive age (32). It is diagnosed using the Rotterdam criteria (33) which requires at least 
two of three criteria to be met for diagnosis. These include oligo- or anovulation, clinical or 
biochemical hyperandrogenism and the polycystic appearance of ovaries on ultrasound scan. 
Women with PCOS have a higher number of antral follicles as compared to women without 
PCOS (34). The density of preantral and small antral follicles in the polycystic ovary is reported 
as six times that of the normal ovary (35). As AMH is expressed by the granulosa cells of the 
antral follicles, it is not surprising that serum AMH levels are higher in women with PCOS as 
compared to women without PCOS (36) (Figure 2-1). Also, women with PCOS have higher 
AMH levels as compared to asymptomatic women with isolated polycystic ovarian 
morphology (PCOM)(36) (Figure 2-1). 
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Figure 3-1 Serum AMH levels in women with PCOS, PCOM and controls. 
Homburg R, Ray A, Bhide P, et al. The relationship of serum anti-Mullerian hormone with 
polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort 
study. Hum Reprod. 2013;28(4):1077-1083. doi:10.1093/humrep/det015 (reproduced with 
permission from the publisher) 
PCOS is commonly associated with ovulatory dysfunction and accounts for 70-75% of all 
anovulatory infertility. As discussed earlier, AMH plays an important physiological role in 
recruitment to the antral follicle pool and cyclic follicular maturation and ovulation (37). Its 
actions are inhibitory to FSH-dependent follicular maturation and ovulation. Given this 
physiological role of AMH, we were keen to further explore the role of AMH in the 
pathogenesis of ovulatory dysfunction in PCOS.  
The high levels of serum AMH in women with PCOS are due to an increased number of antral 
follicles. In our previous work we have demonstrated that these high levels of AMH are not 
only due to the presence of more follicles but also due to a higher per follicle production of 
AMH (38). A ratio of serum AMH to total AFC was calculated for 438 women with PCOS, 
isolated PCOM and women without PCOS, as a measure of AMH production per antral follicle. 
Women with PCOS had a significantly higher AMH/AFC ratio as compared to the other two 
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groups. The per follicle AMH production was not different in women with isolated PCOM and 
controls (Figure 2-2)  
 
 
Figure 3-2 Median AMH/AFC ratios in women with PCOS, PCOM and controls 
Based on data from previously published work - Ref 38 
 
However, PCOS has a diverse reproductive phenotype. Based on the diagnostic criteria of 
oligo-anovulation (OA), hyperandrogenism (HA) and polycystic ovarian morphology 
(PCOM), PCOS may be divided into four phenotypes: Group A (OA+ HA+ PCOM), Group B 
(OA+HA), Group C (HA+PCOM) and Group D (OA+PCOM). Our previous study pooled all 
phenotypes of PCOS and did not evaluate the various phenotypes separately. Therefore, it 
remains unknown if this increased per follicle production is seen across all these clinical 
phenotypes. 
Serum AMH concentrations are significantly higher in anovulatory PCOS as compared to 
ovulatory PCOS (37). We are unsure if this is due to an increased number of follicles or a 
greater per follicle production in anovulatory PCOS. In-vitro studies specifically compared 
women with anovulatory PCOS with controls. Pellatt et al  (2007), demonstrated that the 
granulosa cells from women with anovulatory PCOS produce 75 times higher AMH than size-
matched counterparts without PCOS (28). This is corroborated by other in-vitro studies which 
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a greater expression of AMH mRNA in granulosa cells from women with anovulatory PCOS 
as compared to controls (40). AMH is thought to produce its inhibitory effect on follicular 
maturation by decreasing the sensitivity of the follicles to FSH through the inhibition of FSH 
induced aromatase expression. This is supported by in-vitro studies that demonstrate a reduced 
aromatase mRNA expression in granulosa cells treated with AMH (28, 31). 
The above results led us to postulate that high intra-follicular concentrations of AMH due to a 
greater per follicle AMH production, may result in a heightened inhibitory response to 
follicular maturation and ovulation. This may result in the ovulatory dysfunction associated 
with PCOS. We hypothesized that the anovulatory phenotypes of PCOS have a greater AMH 
production per follicle as compared to the ovulatory phenotypes. If true, this would support the 
postulated mechanism of anovulation. 
We were hence keen to explore the greater per follicle production of AMH amongst various 
phenotypes of PCOS. We also wanted to explore other factors that might be associated with a 
higher per follicle production of AMH, such as levels of luteinising hormone (LH), androgen 
and insulin. 
3.5 Factors affecting ovarian reserve 
Wallace et al (2010)(41) developed a model of human ovarian reserve (primordial follicles) 
from conception to menopause, combining histological evidence from literature (Figure 2-3). 
The simple peak model demonstrated a steady decline in primordial follicle numbers after 20-
22 weeks of gestation and reported the main determinant of remaining ovarian reserve (81%) 
to be time, with environmental and genetic factors accounting for much of the remaining 
variation. When reporting on the ovarian reserve in a sub-section of the population from 
conception to 25 years, 95% of the variation in the ovarian reserve could be attributed to age 
alone. The remaining 5% variation was thought to be due to other factors. The authors 
speculated that as chronological age increased the role of factors other than age became more 
important in influencing ovarian reserve.  
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Figure 3-3 Model of human ovarian reserve from conception to menopause. 
Wallace WH, Kelsey TW. PLoS One. 2010;5(1):e8772. Published 2010 Jan27. (Open access 
article) 
 
Kelsey et al (2011), developed a model of serum AMH values from conception to menopause 
to represent the antral follicle pool (42) (Figure 2-4). This reported a peak in the neonatal 
period, an increase in serum AMH throughout childhood to young adulthood with a dip at 
puberty, followed by a steady decline to menopause. This model reported only 34% of the 
variation in serum AMH to be due to age with the remaining two third of the variation attributed 
to other factors.  
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Figure 3-4 Model of serum AMH from conception to menopause. 
Kelsey TW et al . PLoS One. 2011;6(7):e22024. (Open access article) 
The size of the antral follicle pool is more dynamic than the primordial follicle pool. Its size is 
influenced by factors other than the size of the primordial pool. As well as time, genetics and 
environment, the complex endocrine and paracrine environmental changes associated with 
early life, puberty and peri-menopause may also affect AMH levels at a given age. Although 
there remains a steady decline in primordial follicles from 22 weeks of gestation to menopause, 
the rate of recruitment from the primordial to the antral follicle pool is variable. It increases 
from birth throughout childhood to peak at the age of 14 years, and then decreases to 
menopause (41). Hence, before 25 years, serum AMH and ovarian reserve are much less well 
correlated, with increasing serum AMH suggesting an increased recruitment and high ovarian 
activity rather than high ovarian reserve.  
In the adult population, after peak serum AMH levels reached at the age of 24.5 years, there 
was a strong positive correlation (r = 0.96) between declining primordial follicles and declining 
serum AMH (43). This is supported by the study by Hansen et al detailed above (14). Hence 
after about 25 years of age, the trajectories for primordial follicles and serum AMH may be 
considered similar, with serum AMH thought to be a fairly accurate, although indirect marker 
of the primordial follicle pool.  
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From the above it is clear that in addition to age, genetic, lifestyle and environmental factors 
are recognised determinants of variation in ovarian reserve. It is hence reasonable to use 
available markers to estimate ovarian reserve in addition to age alone.  
Literature has produced contradictory findings for the effect of genetic and lifestyle exposures 
on ovarian reserve. It is often difficult to ascertain the effect of a single factor as these factors 
may coexist and be difficult to separate. We are also unsure as to the mechanisms by which 
these factors may affect ovarian reserve and if their effects may be reversible. Self-reporting 
may also introduce a bias due to under-reporting. The literature reports conflicting results for 
the impact of ethnicity on ovarian reserve. Several studies report differences in serum AMH 
amongst women from different ethnicities (44-47) in contrast to others who report no 
differences (48, 49). These conflicting results may be attributed to heterogenous populations, 
small sample sizes, and confounding environmental factors. True biological variation in 
ovarian reserve due to ethnic differences may be confounded by varying environmental 
conditions the effect of which may be difficult to separate. Reporting bias due to self-reported 
ethnicity may also result in discordant results. Olcha et al (2016), assessed the relationship 
between genetic ethnicity using ancestry related markers and markers of ovarian reserve. They 
found no differences in serum AMH or AFC relative to genetic ethnicity (50). Conditions such 
as PCOS are more common in some ethnicities and may account for ethnic differences  reported 
(48).  
BMI is not thought to affect ovarian reserve markers. Although some studies reported 
differences, these were attributed to differences in age amongst the groups compared (51). 
Further studies demonstrate no effect of BMI on ovarian reserve markers (52-54).  
Hawkins et al (2016),(55) reported lower levels of serum AMH with current, frequent binge 
drinking in a large population-based study. Other behaviours such as past history of alcohol 
intake, ever-drinking, number of drinks per day or daily consumption did not show a similar 
association. This was in contrast to other studies which did not demonstrate any differences 
(53, 56). Pregnancy, oral contraceptive pill (OCP) use, hypothalamic-pituitary suppression 
with GnRH analogues or states such as hypothalamic amenorrhoea are known to reversibly 
decrease levels of ovarian reserve markers such as serum AMH (57-61). However, studies on 
the effect of cigarette smoking on ovarian reserve parameters have reported contradictory 
findings.  
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In view of the contradictory results reported in published literature we decided to 
systematically review the effect of cigarette smoking on the quantitative ovarian reserve 
parameters, serum AMH and AFC. 
3.6 Effect of smoking on ovarian reserve. 
I have conducted a systematic review of the literature to assess the effect of cigarette smoking 
on the quantitative ovarian reserve parameters, AMH and AFC.  
I searched for all types of published literature reporting the effect of smoking on ovarian reserve 
parameters and included all types of studies published as primary research involving humans 
published as full text manuscripts in English language. I assessed the quality of the included 
studies using the Newcastle-Ottawa scale (NOS) modified for observational studies (62). I 
further modified the scale as only non-interventional observational studies were included. I 
conducted a comprehensive search for eligible studies to minimise the impact of reporting bias. 
The outcome measures were markers of ovarian reserve; either serum AMH or AFC. I screened 
and identified relevant studies for the review using the electronic database MEDLINE from the 
inception of the database till 30/10/2019 and hand searching as described by Cochrane 
methodology (63). The search strategy included a combination of subject headings (MeSH) 
and text words relating to or describing the exposure/risk factor (smoking/cigarette smoking) 
and outcomes (ovarian reserve/egg reserve/AMH/AFC). The reference lists of the primary 
articles were searched for relevant citations not captured by the electronic searches. 
After screening the titles and abstracts of articles retrieved from the search, I obtained and 
reviewed the full texts of potentially suitable articles. I extracted and collected the data from 
the selected articles on a bespoke data collection Excel spreadsheet. I collected data for study 
design, methodological characteristics, participant characteristics, methods for assessment of 
smoking exposure and outcomes. If a study was reported in multiple publications, I pooled 
these together under a single study ID.  
The search of the MEDLINE electronic database retrieved 94 studies. Hand searching retrieved 
one additional study. After screening of the titles and abstracts, the full text of 22 studies were 
retrieved. 20 of these were selected for the review and two excluded.  
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All included studies were of an observational design. 19 studies were of a cross sectional design 
(53, 55, 56, 64-79) and one of a longitudinal study design (80). 11 studies were population 
based (53, 55, 64-71, 80) studies whereas the other nine were single centre hospital-based 
studies (56, 72-79). 
Participants in population-based studies were volunteers recruited from larger cohorts. Those 
in single centre studies were infertile women undergoing fertility treatment. Ascertainment of 
smoking exposure in all studies was through self-reported smoking history. Some studies 
included an in-depth questionnaire to detail smoking exposure and quantify it; others only 
classified them into crude categories without details of intensity or duration of exposure.  None 
of the included studies used objective methods to confirm exposure to smoking such as urine 
cotinine testing or a breath test for carbon monoxide (CO). Studies either dichotomized women 
into smokers and non-smokers or categorized them into three groups; current smokers, ex-
smokers and never smokers. The inclusion or exclusion of passive smoking was also variable 
amongst included studies. 18 studies reported serum AMH levels, and six on AFC.  
Significant methodological heterogeneity was observed in the included studies. This related 
mainly to the participant population included and assessment of smoking exposure. All studies 
used validated measurements for the outcomes reported, considered the effect of confounding 
variables in either study design or analysis, and used appropriate statistical methods for 
analysis. The quality of evidence of individual studies assessed by the NOS was good to very 
good in 19 of the 20 studies. One study was considered satisfactory and none of the studies 
was considered unsatisfactory.  
The included studies showed no consistent direction of effect for serum AMH. 10 studies 
reported no differences in serum AMH levels between smokers and non-smokers. The other 
eight reported a significant negative impact of smoking on serum AMH levels.  
Bressler (2016) (55), in a large population-based study, including 1654 participants, with a 
detailed analysis of smoking history was unable to demonstrate significant differences in serum 
AMH levels between any groups. These conclusions were reiterated in studies by Dafopoulos 
et al (2010) (73), Freour et al (2010) (75), Freour et al (2012) (76), Jung et al (2017) (64), Kline 
et al (2016) (66), La Marca et al (2013) (69), Nardo et al (2007) (56), Szkup et al (2018) (68) 
and Waylen et al (2010) (79). In contrast, Dolleman (2013) (53)  in an earlier population-based 
study in 2013, including 2320 participants, reported a significantly lower level of serum AMH 
in current smokers as compared to never smokers. No differences were noted between never 
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smokers and ex-smokers. Similar result was reported by Dolleman et al (2015) (81), Freour et 
al (2008) (82), Freour et al (2013) (77), Fuentes et al (2012) (78), Plante et al (2010) (71), 
Sowers et al (2010) (67) and White et al (2016) (70). 
A significant negative correlation between intensity of smoking and serum AMH was reported 
by Dolleman et al (2013) and similarly by Freour et al (2008) and Fuentes et al (2012). 
Two of the six studies reporting AFC reported a negative impact of smoking on AFC. Caserta 
et al (2013) (72) and Freour et al (2013) reported significantly lower AFCs in smokers as 
compared to non-smokers. Four other studies, Freour et al (2010), Freour et al (2012), Kinney 
et al (2007) (65) and Nardo et al (2008) could not demonstrate a significant difference between 
groups. 
This review of literature showed no consistent direction of effect of smoking on serum AMH 
or AFC and hence for a quantitative change in the antral follicle pool following exposure to 
cigarette smoking. In relation to the effect of smoking on ovarian reserve it is important to 
assess serum AMH and AFC for two reasons. Firstly, these biomarkers are important as they 
allow estimation of response to ovarian stimulation and planning of fertility treatment 
protocols, which are crucial to success rates of treatment. Secondly, this may provide valuable 
insight into the possible mechanisms for the effects.  
Animal studies have suggested adverse effects of cigarette smoke on ovarian reserve (83, 84). 
Several mechanisms have been postulated, which may affect quality, quantity or both. Gannon 
et al (2012),(85) hypothesised a mechanism of direct toxicity to ovarian follicles resulting in 
an accelerated follicle loss. An indirect effect on ovarian follicle numbers has been suggested 
through an action on the hypothalamic pituitary axis (86). The effects through either 
mechanism would mirror decreased levels of AMH and AFC. Suboptimal oocyte quality due 
to the presence of a greater concentration of reactive oxygen species has also been suggested 
(84). Impairment in granulosa cell proliferation and oocyte development were observed in 
animal models and these effects continued after cessation of exposure (87). These effects would 
be better reflected by outcomes such as embryo quality and pregnancy rates rather than serum 
AMH and AFC.  
Published literature from clinical studies is contradictory and inconclusive as evidenced by this 
review. This may be attributed to several factors. Characteristics of participant populations in 
reported studies are heterogeneous in terms of age, fertility and ethnicity amongst other factors. 
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The natural decline of ovarian reserve with age does not follow a linear function but shows a 
rapid decline with increasing age(41). It may be more challenging to demonstrate significant 
differences amongst groups in younger populations with higher and less dispersed baseline 
values for serum AMH and AFC. This may account for discordance in the results of the two 
largest studies included in this review. The mean age of participants in the study by Dolleman 
et al (2013), which reported negative effects of current smoking was 37.3 (SD 9.2) years. In 
comparison, the mean age in the study by Bressler et al (2016), which was unable to find a 
significant association was only 29 (SD 4) years.  It has also been suggested that ovarian 
follicles may differ in susceptibility to the effects of smoking at different ages with older 
oocytes being more susceptible to negative effects of smoking. Additional information in future 
studies may be obtained from the use of longitudinal data. Although ovarian reserve parameters 
are most relevant for fertility, the use of infertile/subfertile women may introduce an additional 
confounder. Hence population-based studies in a comparable age group may be considered 
most appropriate. 
The second important factor contributing to contradictory results are differences in 
ascertainment of exposure to cigarette smoke. Several studies included in this review did not 
categorise ex-smokers separately and did not account for passive smoking. This leads to 
contamination of the two broad study groups; smokers and non-smokers. Ex-smokers and 
passive smokers included in the group of non-smokers may reduce mean differences between 
groups and the effect sizes of outcomes. This can lead to differences in significance levels of 
outcome measures reported. It is unknown if the possible negative impact of smoking affects 
all follicles in the ovary or only the antral follicle pool. If the effect is restricted only to antral 
follicles, it would explain the lower levels of AMH in current smokers but not in ex-smokers. 
This reinforces the need for categorising ex-smokers separately. 
Studies have used variable definitions for current and non-smokers. Freour et al (2008) and 
Bressler et al (2016) include participants who quit smoking within one year as current smokers 
in contrast to Plante et al (2010) who has extended this definition to two years. As the effects 
of smoking on ovarian reserve are likely to be dose and duration dependant, it remains 
important to include details of the duration and intensity of smoking exposure. All of the above 
may be considered serious flaws in study design. Self-reported smoking histories may also be 
considered flawed due to inaccuracies of reporting. More objective measures of current 
smoking may be considered more robust for future study designs. 
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In conclusion, a review of the literature is unable to provide evidence of a quantitative change 
in ovarian reserve markers following exposure to smoking. Although the review does not 
provide definitive evidence of effect, it very clearly highlights the heterogeneity of existing 
literature. I consider this useful new information to direct future research.  
Based on this systematic review we planned to assess the effect of cigarette smoking on the 
quantitative ovarian reserve parameters, validating self-reported smoking behavior using 
biomarkers. 
3.7 Effect of insulin sensitisers on ovarian reserve 
Since the seminal report by Burghen et al (1980) of the association of hyperinsulinemia and 
PCOS (88), and the significant publication by Dunaif et al (1989) which reported that women 
with PCOS have intrinsic insulin resistance (IR) independent of obesity (89), IR is widely 
reported at 50-70% in women with PCOS (90). Using the euglycemic–hyperinsulinaemic 
clamp method which remains the gold standard for assessment of insulin resistance, Dunaif et 
al (1989)(89) and more recently Stepto et al (2013 )(91) supported the concept of intrinsic IR 
in PCOS. Intrinsic IR is independent of BMI but exacerbated by any increase in BMI. Stepto 
et al (2013) reported a 75% incidence of IR in lean PCOS and a 95% incidence of IR in obese 
PCOS. They reported a significantly increased incidence of IR in lean PCOS as compared to 
lean controls (p = 0.038). This concept still remains controversial but is supported by some 
studies hypothesising the mechanisms for intrinsic IR (92, 93).  
The cause for intrinsic IR in PCOS remains unknown and several mechanisms have been 
postulated. Zhang et al (1995), proposed that a single factor that causes serine phosphorylation 
of the insulin receptor and serine phosphorylation of P450c17, the key regulatory enzyme 
controlling androgen biosynthesis, could produce both the insulin resistance and the 
hyperandrogenism characteristic of PCOS (94). Atypical insulin receptors and insulin 
signalling pathways have been proposed (92, 93). Inositols which are members of the vitamin 
B complex family are also hypothesised to play an important role in insulin and glucose 
metabolism as mediators in the signal transduction system. The major stereo-isomers d-chiro 
inositol and myo-inositol are hypothesised to play different physiological functions. D-chiro 
inositol is involved in insulin mediated androgen synthesis in the theca cells (95), whereas 
myo-inositol is involved in the FSH signalling pathway, glucose uptake and metabolism within 
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the cells. Myo-inositol is converted to d-chiro inositol by the action of the enzyme epimerase 
which is stimulated by insulin. Hence in states of hyperinsulinemia there is an increased 
production of d-chiro inositol and relative deficiency of myo inositol leading to increased 
androgen synthesis (96). Misso et al (2013), suggested that insulin sensitisers may be more 
effective in lean women with PCOS suggesting different mechanisms and hence treatment 
strategies for extrinsic and intrinsic IR (97). Weight loss interventions and decrease in visceral 
fat may help to reduce extrinsic IR, insulin sensitisers may be more effective in treating 
intrinsic IR (98).  
Insulin resistance and hyperinsulinemia are thought to play a central role in the 
pathophysiology of PCOS through their actions on ovarian steroidogenesis. Syndromes of 
severe insulin resistance and hyperinsulinemia are associated with hyperandrogenism (99, 
100). The defect in the action of insulin in these conditions of insulin resistance is thought to 
be selective for glucose metabolism but not for steroidogenesis (93). Insulin in high 
concentrations has shown to stimulate estrogen, androgen and progesterone secretion in-vitro 
(101) which has led to the hypothesis that hyperinsulinemia leads to hyperandrogenism. 
Although insulin receptors are present in ovarian tissue, it has been proposed that one of the 
mechanisms of action of insulin on ovarian steroidogenesis is mediated through its action on  
IGF-1 receptors (102). Insulin may also act through its own receptors on theca and granulosa 
cells to mediate hyperandrogenism by stimulation of ovarian steroidogenesis (95, 103) but also 
by stimulation of LH release by the pituitary. The actions of insulin on steroidogenesis are 
observed only in women with PCOS and not on normal women (104). This suggests that the 
pre-condition of polycystic ovaries must be present for hyperinsulinemia to produce 
hyperandrogenism.  
Androgens produced by the theca cells stimulate ovarian folliculogenesis. Thus, an increased 
androgen production and hyperandrogenism secondary to hyperinsulinemia has the potential 
to increase folliculogenesis in women with PCOS.  
Based on this background, treatment of insulin resistance with insulin sensitisers has the 
potential to reduce hyperandrogenism and subsequently affect folliculogenesis and the antral 
follicle pool. We planned to assess the effect of treatment with myo-inositol (MI)/di-chiro 
inositol (DCI) compared to no treatment, placebo or other treatment on markers of ovarian 
reserve in women with PCOS combining data from all published literature. 
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3.8 Prediction of natural fertility using ovarian reserve markers 
Age remains one of the most important determinants of female reproductive function and 
fertility. A natural age-related decline in fertility is due to a decline in the number of oocytes 
and also a reduction in oocyte quality. Ovarian reserve markers such as serum AMH and AFC 
are able to demonstrate a decrease in the number of oocytes with increasing age. However, 
evidence for their role for prediction of natural fertility remains limited and contradictory. 
Steiner et al (2011)(105) in a prospective study, reported time to pregnancy in a community 
sample of 100 women trying to conceive for less than 3 months and with no history of 
infertility. As expected, age remained a strong predictor of pregnancy with women older than 
35 years having a significantly lower probability of pregnancy than younger women (FR=0.42, 
95% CI: 0.15, 0.85). They reported significantly reduced pregnancy rates in women with serum 
AMH levels of 0.7 ng/ml or less as compared to women with higher serum AMH levels even 
after adjusting for age (FR=0.38; 95% CI:0.08, 0.91). Hagen et al (2012)(106) recruited 430 
couples who planned to discontinue contraception with a view to become pregnant and reported 
pregnancy rates in women with a low, medium and high level of serum AMH. They concluded 
that low serum AMH was not a good indicator of natural conception and pregnancy. They 
attributed this to be due to high oocyte quality inspite of a reduced ovarian reserve. The cohort 
of women in the study by Hagen et al (2012) were younger (19-35 years) as compared to the 
women in the study by Steiner et al (2011) (30-44 years). This along with the differing 
covariates analysed could account for these contradictory results.  
It is difficult to study the effects of oocyte and embryo quality in the context of natural fertility. 
Age related decline in oocyte quality is thought to be related to abnormalities in meiotic spindle 
formation and chromosomal alignment resulting in an increased incidence of aneuploidy (107). 
Age related abnormalities in mitochondrial DNA are also reported to contribute to reduced 
oocyte quality (108).  
In the absence of data and adequate evidence, the use of serum AMH and AFC for general 
fertility assessment and prediction of spontaneous conception in the general population is not 
recommended.  
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3.9 Ovarian reserve markers and outcomes of fertility treatment 
A successful outcome following IVF treatment is strongly predicted by the quality of 
transferred embryos (109). Published literature is however unable to demonstrate a clear 
correlation between embryo quality and ovarian reserve/markers of ovarian reserve. Sunkara 
et al (2011) demonstrated a strong positive correlation between the number of oocytes retrieved 
at IVF and live birth rates (110). They analysed data from 400,135 fresh IVF cycles and 
demonstrated an increase in live birth with an increase in the number of retrieved oocytes, up 
to 15 oocytes with a plateau and decline thereafter across all age groups. Serum AMH and AFC 
correlate well with the response to controlled ovarian stimulation and the number of oocytes 
retrieved at IVF (111, 112). Further to this, a positive correlation between serum AMH and 
pregnancy rates following IVF has been reported  (112-114). It may be argued that this positive 
relationship may be indirect and attributed purely to an increased probability of having good 
quality embryos for embryo transfer due to a greater number of retrieved oocytes. Some 
researchers report contradictory findings to the positive correlation discussed above (115, 116). 
Wang et al (2010) analysed 2712 fresh IVF cycles and concluded that the correlation between 
serum AMH and clinical pregnancy rates was modulated by age. The predictive value of serum 
AMH decreased at ages above 42 years where oocyte quality remained the more important 
predictor of outcome. Oocyte and subsequent embryo quality is negatively influenced by age 
due to an increase in the incidence of chromosomal abnormalities and aneuploidy (107, 108).  
Variation in reported literature on the association between ovarian reserve markers and embryo 
quality may be attributed to differing ovarian stimulation protocols used, variable timings for 
embryo transfer and differing time points during IVF for measurement of serum AMH. 
Additionally, there may be variation due to different methods used for assessing embryo 
quality. Assessment of embryo quality in standard IVF treatments is through a morphological 
assessment of embryos using a light microscope at fixed time points following fertilisation. 
This assessment, although following a standardised system (117) is liable to inter-observer 
variability, can be subjective and may contribute to inconsistency in results (118). The use of 
a time lapse incubator with the use of morphokinetic parameters provides more objective and 
reproducible estimates of embryo quality as compared to standard morphological assessment. 
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Assessments of embryo quality done on day 3 following fertilisation have poorer correlation 
with outcomes as compared to extended culture and embryo assessment on day 5 (119). 
Assessment of embryo quality on day 5 rather than day 3 allows better embryo selection.  
Based on this background, we were keen to assess the association between ovarian reserve and 
embryo quality using the newer technology of time lapse imaging. We planned to examine the 
correlation between baseline serum AMH levels as a marker of ovarian reserve and ‘KID’ 
(Known Implantation Data) scores of the developing embryos generated by time lapse imaging 
as an indicator of embryo quality also considering the effect of important confounders. 
3.10 Aims and objectives 
The overarching aim of this thesis was to study the role of the ovarian reserve markers, AMH 
and AFC, on different aspects of fertility and fertility treatment. The thesis comprised of four 
work packages. Their individual aims and objectives are as below. 
1) To compare the per follicle AMH production (expressed as a ratio of serum AMH to 
the total AFC) in the various phenotypes of women with PCOS and with isolated 
PCOM. We also aimed to evaluate the factors which may be associated with variation 
in AMH production among these different clinical phenotypes. 
2) To assess the effect of cigarette smoking on the quantitative ovarian reserve parameters 
in sub-fertile women, validating self-reported smoking behavior using biomarkers 
(breath carbon monoxide levels and urine cotinine levels). 
3) To assess the effect of treatment with myo-inositol (MI)/di-chiro inositol (DCI) 
compared to no treatment, placebo or other treatment on markers of ovarian reserve in 
women with PCOS combining data from published literature. Our secondary aim was 
to assess the effect of these treatments on reproductive outcomes in women with PCOS 
undergoing IVF/ICSI. 
4) To assess the association between ovarian reserve markers and embryo quality in 
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4 Materials and methods 
I conducted the work contributing to the thesis between 2014 and 2020. Although I was 
formally registered as a PhD student in January 2016, I started the planning, discussion and 
preparatory work in 2014 and continued it in the 18 months preceding registration. A timeline 
for the four work packages which make up the thesis is as shown below. 
 
 
Figure 4-1 A timeline for the work packages for the thesis 
 
I have used a combination of primary research and evidence synthesis for the different work 
packages. Three work packages were observational studies constituting primary research and 
one was a systematic review and meta-analysis. 
For the purposes of the thesis I will refer to these as 
Paper I: PCOS phenotypes and AMH 
Paper II: Smoking and ovarian reserve markers 
Paper III: Systematic review on inositols and ovarian reserve 
Paper IV: Serum AMH and embryo quality 
4.1 Primary research 
4.1.1 Study design 
We have used a cross-sectional study design for all the three primary research studies. The 
studies were observational without any active intervention, treatment or deliberate exposure. 
4.1.2 Setting and population 
All the primary research projects were single centre studies conducted at the Homerton Fertility 
Centre, London, UK. This is a tertiary referral fertility centre within a university teaching 
hospital. It sees more than 1500 new couples per year for investigations and treatment, offers 
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the full range of assisted conception treatments and performs approximately 1000 IVF/intra-
cytoplasmic sperm injection (ICSI) treatments annually. 
 
Figure 4-2 Homerton University Hospital, London, UK 
 
The women included for all primary studies included in the thesis were patients at the fertility 
centre. Being an inner-city hospital in East London, this centre treats a wide range of multi-
cultural and multi-ethnic populations. Fertility treatments here are predominantly funded by 
the National Health Service (NHS). As NHS funded fertility treatments are restricted based on 
factors such as age and BMI, this is reflected in the population of women seen in clinics and 
hence included for the research studies. 
4.1.3 Inclusion and exclusion criteria 
We have attempted to minimise the bias which is inherent to observational studies in the design 
stage by selecting appropriate inclusion criteria for each of the three studies. 
Paper I: PCOS phenotype and per follicle AMH production: The inclusion criteria included all 
women with PCOS diagnosed by the Rotterdam criteria (33) or isolated PCOM. The Rotterdam 
criteria are globally accepted criteria with validated definitions for its individual components. 
The diagnosis of PCOS requires two of the three criteria to be satisfied. 
1 Oligo-anovulation (OA) 
2 Clinical or biochemical hyperandrogenism (HA) 
3 Polycystic ovarian morphology on ultrasound (PCOM) 
Table 4-1 Rotterdam criteria for the diagnosis of PCOS 
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Oligo-anovulation (OA) was defined as menstrual cycle length beyond of the range of 23-35 
days (120). Clinical hyperandrogenism (HA) was defined by the presence of hirsutism 
(modified Ferriman Gallwey score (mFG) of ³ 8) or acne (121). Biochemical HA was defined 
as a Free Androgen Index (FAI) of greater than 3.36 (122). PCOM was defined as the presence 
of at least 12 antral follicles, 2-9 mm,  on at least one ovary (123) 
 
Figure 4-3 Polycystic ovarian morphology on 2-dimensional ultrasound scan 
 
Women with PCOS were divided into four phenotypes based on the diagnostic inclusion 
criteria of OA, HA and PCOM. These included Group A (OA+ HA+ PCOM), Group B 
(OA+HA), Group C (HA+PCOM) and Group D (OA+PCOM). 
 OA HA PCOM 
PCOS-A + + + 
PCOS-B + +  
PCOS-C  + + 
PCOS-D +  + 
Table 4-2 Clinical phenotypes of PCOS 
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Paper II: Smoking and ovarian reserve markers: We included women £ 35 years attending the 
fertility centre for investigations and treatment. We excluded women on long term oral 
contraceptive pills or GnRH analogues, women not having both ovaries, those with previous 
chemotherapy, abdominal/pelvic radiotherapy or major ovarian surgery.  
Paper III: AMH and embryo quality: We included all women undergoing IVF/ICSI, those with 
single and double embryo transfers and those with day 3 or day 5 embryo transfers. However, 
in order to allow a direct correlation of embryo quality to clinical pregnancy, a secondary 
outcome, only those women with known implantation data were included. This included all 
women with a single embryo transfer and those women with a double embryo transfer who 
either had a negative pregnancy test or a dichorionic twin pregnancy. We included only those 
women who had their embryos cultured and assessed in the time lapse incubators. 
4.1.4 Screening, consent and the care pathway 
We screened the medical notes of women attending the fertility centre for eligibility for all 
three studies. For papers I and IV consent was not required from individual participants but 
this was required for paper II, which assessed ovarian reserve markers and cigarette smoking. 
Potentially eligible participants were invited to participate in the study and informed consent 
was obtained from those who agreed. As the research did not involve any active intervention 
or treatment the standard care pathway for all participants remained unchanged. 
4.1.5 Study procedure/intervention 
Paper I: We measured serum AMH and a total AFC for each participant. A ratio of serum AMH 
to the total AFC was calculated as a marker of AMH production per follicle and expressed as 
the AMH/AFC ratio. We also collected data for other baseline and confounding variables. 
These included age, BMI, waist-hip ratio, mFG score, serum FSH, serum LH, T, SHBG, fasting 
glucose and fasting insulin. 
Paper II: We assessed the participants for markers of smoking. This included a short self-
reported questionnaire about the participant’s current and past smoking history, a non-invasive 
breath test to detect the levels of CO and a urine test to detect the levels of cotinine. Based on 
the smoking history we classified participants into one of three categories; current smokers, 
ex-smokers and never-smokers. The smoking history also accounted for passive smokers and 
smoking details which allowed us to quantify the smoking exposure in terms of “pack years”. 
We measured serum AMH and AFC as a part of the standard fertility work up done for all 
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fertility patients. We collected data for baseline and confounding variables such as age, 
ethnicity, BMI, presence of PCOM/PCOS and a history of ovarian surgery. 
Paper IV: We measured baseline serum AMH before start of treatment for all participants. We 
assessed embryo quality using the time lapse incubators and the computerised KID score. We 
collected data for confounding variables such as age, BMI, smoking status and method of 
insemination (IVF/ICSI). 
4.1.6 Devices, techniques and tools, laboratory procedures 
Serum AMH measurement 
The AMH assay has rapidly evolved over the last 30 years. Early years saw single laboratory 
versions of the AMH assay. This was followed by the development of two commercial assays, 
the Immunotech Beckman Coulter (IOT) assay introduced in 1999 and the Diagnostic Systems 
laboratory (DSL) assay in 2003. The primary antibodies used and the calibration standards 
were different for the two assays. Hence the reported values also differed.  The IOT assay had 
antibodies directed towards the pro-region and the mature regions as compared to the DSL 
assay which had both antibodies directed to the mature region to minimise against proteolysis. 
The two assays were then consolidated to a single assay – the AMH Generation II Beckman 
Coulter (Gen II) assay. This used the antibodies from the DSL assay and the calibration 
standards from IOT. The AMH measurements for two studies in the earlier timeframes of the 
project (Paper I and Paper IV) used the Beckman Coulter Generation II assay. The results were 
presented in pmol/l. With an on-site laboratory, the samples were delivered, spun, and stored 
at -20°C, and analysed within 14 days. A further assay, the ultrasensitive ELISA assay (Ansh 
Labs) was also developed. This was followed by the introduction of two fully automated AMH 
assays, the Access assay (Beckman Coulter) and Elecsys assay (Roche). The values from the 
Access assay are identical to the Gen II assay. The Access and Elecsys assays use identical 
antibodies but differ in calibration. Hence, values generated by different assays differ and assay 
specific interpretation is required. The last study done for the thesis, Paper II, used the Beckman 
Coulter Access assay. Venous blood samples were obtained and delivered to the on-site 
laboratory immediately, centrifuged, stored at 2-8°C, and analysed every day. 
Some issues have been reported for the Gen II assay following long term storage and transport 
of samples.  However, this did not impact any of the measurements for our studies due to the 
availability of an on-site laboratory and quick processing of samples. 
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Measurement of serum AMH was not restricted to a particular time of the cycle due to low  
intra-cycle variability (124) 
Measurement of AFC 
Ultrasound measurement of the antral follicle count can be done by manual measurement using 
two dimensional ultrasound. This process is however labour intensive and prone to errors 
especially for smaller sized follicles and ovaries with a large number of antral follicles. 
Substantial intra-observer and inter-observer variability is reported for the use of this method.  
 
 
Figure 4-4 Two dimensional ultrasound image of the ovary 
 
Three dimensional (3D) ultrasound coupled with an automated software which allows the 
assessment of the number and size of follicles reduces intra- and inter-observer variability and 
improves accuracy of measurement (125, 126).The software used identifies hypoechoic fluid 
filled structures as follicles and hence may sometimes detect structures other than ovarian 
follicles and interpret these to be antral follicles. Thus, image postprocessing is necessary to 
remove these artefacts.  
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Figure 4-5 Three-dimensional ultrasound images of ovary demonstrating the technique of 
automated antral follicle count using sono-AVC software 
 
All ultrasound measurements of the AFC for our studies was done by trained fertility doctors 
using 3D ultrasound with automated follicle counting software sono-AVC™ and manual image 
post-processing. We used the Voluson E6 diagnostic ultrasound system (GE Medical Systems) 
equipped with a multi-frequency transvaginal probe (RIC5-9-D: 4-9MHz) for the earlier study 
on PCOS phenotype. For the last study done in 2019-20 we used a similar but newer machine, 
the Voluson S10 diagnostic ultrasound system (GE Healthcare) equipped with a multi-
frequency transvaginal probe (RIC5-9W-RS: 9-5MHz). 
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Figure 4-6 Diagnostic ultrasound systems (GE Voluson S10) used for imaging ovaries  
 
Hormonal profiles 
We assessed the detailed hormonal profiles of women included in Paper I which included 
women with PCOS. We measured levels of pituitary gonadotropins, serum FSH and serum LH 
using enzyme linked immunosorbent assay (ELISA). These were measured in the early 
follicular phase of the menstrual cycle when they are at their lowest level. Measurement of 
androgens is an important part for the diagnosis and characterisation of women with PCOS. It 
is recommended that either the calculated free testosterone, free androgen index or calculated 
bioavailable testosterone should be used to assess biochemical hyperandrogenism for the 
diagnosis of PCOS.  Assays such as liquid chromatography–mass spectrometry (LCMS) and 
extraction chromatography immunoassays are recommended for the most accurate assessment 
testosterone (127, 128). We measured serum total testosterone using mass spectrometry (MS) 
coupled with liquid chromatography (LC)(LCMS) and results expressed as nmol/l. Serum 
insulin and SHBG were measured using chemiluminescent microparticle immunoassay. 
Measurement of other variables  
Body-mass index (BMI): This was calculated using a standardised formula: 
BMI=weight(kg)/height(m)2 The weight of the woman was measured in light clothing without 
shoes using an electronic scale  and the height was determined using an altimeter. 
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Waist-hip ratio: The waist measurement was done at the mid-point between the lower rib 
margin and the iliac crest. The hip measurement was taken at the widest point of the hips. All 
measurements were expressed in centimetres and a waist-hip ratio calculated. 
 
Modified Ferriman Gallwey (mFG) score: This was assessed as a measure of clinical 
hyperandrogenism for women with PCOS. This score assesses excessive hair growth in nine 
body regions on a scale of 1-4. A maximum score of 36 is possible. A score of ³ 6-8 is 
considered to represent clinical hyperandrogenism (129). We used a self-reported assessment 
by participants asking them to use information prior to cosmetic measures taken to treat 
hirsutism. It may be argued that objective physician assessment may be more accurate than a 
patient-reported assessment. Although theoretically correct, women regularly use several 
cosmetic measures such as shaving, waxing, epilating, bleaching, threading and laser treatment 
for this. Hence assessment carried out in the centre is more likely to be an inaccurate measure 
of the extent of hirsutism. We have used a cut off of a score of ³ 8 for our study. 
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Questionnaires for smoking assessment 
We used a bespoke questionnaire to obtain a self-reported smoking history for this study. We 
designed the questionnaire with the input of clinical and research members of the team to 
ensure content validity and reliability. We then tested this on a pilot sample of the target 
population. This highlighted deficiencies and allowed improvements in the final questionnaire 
used. 
Carbon monoxide (CO) measurement 
We measured breath CO as a biomarker of smoking as a part of the study to assess the effect 
of smoking on ovarian reserve markers. The device used to measure the breath CO 
(Smokelyser) is a CE marked, commercially available, non-invasive CO breath test that uses 
an electrochemical sensor to measure the breath concentration of CO with a concentration 
range of 0-150 ppm with a sensor sensitivity of 1 ppm and an accuracy of ±2 ppm. The 
instrument was used within the specified warranty period and used and serviced according to 
manufacturer’s specifications. 
 
Figure 4-8 Smokelyser used for breath CO measurement 
Urine cotinine measurement 
We also measured urine cotinine as another biomarker of smoking. The urine cotinine was 
measured using the DRI®Cotinine assay (Thermo Fisher Scientific). The DRI® Cotinine 
Assay is an in vitro diagnostic medical device intended for the qualitative and semi-quantitative 
determination of cotinine in human urine at a cut off level of 500 ng/mL. The accuracy of the 
assay has been confirmed by gas chromatography /mass spectrometry. According to 
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manufacturer, the sensitivity, defined as the lowest concentration that can be differentiated 
from the negative urine calibrator with 95% confidence, is 34 ng/mL. 
Calculation of pack years 
We calculated pack years using the standard formula: Number of pack-years = (packs of 
cigarettes smoked per day) × (years smoked). One pack equalled 20 cigarettes. 
Embryoscopy and calculation of KID scores 
Embryo incubation and assessment are important steps in the IVF treatment process. Standard 
incubators provide stable and controlled incubation. Embryo assessment is done after 
physically removing embryos from the incubators and examining them under the light 
microscope. This constitutes a snapshot assessment of the embryo at a fixed timepoint. Newer 
time lapse incubators incorporate a camera within the incubator allowing images of developing 
embryos to be taken at intervals of every 5-15 minutes during development. This creates a time 
lapse video of embryo development. The timing of important events in embryo division and 
development called morphokinetic parameters are noted. This information cannot be obtained 
in a standard snapshot assessment. Computerised software allows morphokinetic parameters 
to be collated into a single score which is indicative of embryo quality. Along with the standard 
morphological assessment of embryos this additional information is hypothesised to improve 
the predictive accuracy of embryo selection. Time lapse imaging provides a more reproducible 
and objective method of embryo assessment as compared to standard methodology (130). 
 
 
Figure 4-9 Embryo development from day 2 to day 6 demonstrated by  time lapse imaging in 
an incubator 
We used the Embryoscope time lapse incubators (Vitrolife, Sweden) for our study.  
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Figure 4-10 Embryoscope time lapse incubator 
 
Embryologists placed embryos in the Embryoscope following IVF fertilisation check/ICSI and 
assessed them on day 3 of embryo culture. Five morphokinetic parameters related to timing 
and synchronicity of cell division were noted and these were combined to generate a composite 
score – the KID score. The annotations were, time of pronuclear fading-tPNf, time of first cell 
division to two cells – t2, time of 3 cells – t3, time of 4 cells – t4 and time of 5 cells – t5.  The 
scores ranged between 1-5 with 5 denoting the best embryo quality and 1 a poor embryo 
quality.   
4.1.7 Outcome measures and comparison groups 
Paper I: The primary outcome measure was the AMH/AFC ratio as a marker for per follicle 
AMH production. This was compared in the four phenotypes of PCOS and isolated PCOM. 
The secondary outcome measures were the FAI, homeostatic model assessment (HOMA) and 
serum LH. These were compared in the four clinical phenotypes of PCOS and isolated PCOM 
and their correlation to the AMH/AFC ratio was assessed. 
 
    33 
Paper II: The primary outcome measures were serum AMH and total AFC. These were 
compared between current smokers, ex-smokers and never smokers. The secondary outcome 
measures were lifetime smoking exposure (pack years) and biomarkers of smoking (CO and 
urine cotinine). Biomarkers of smoking were compared between current smokers, ex-smokers 
and never smokers and used to validate the group stratification and the results for the primary 
outcome variables. The pack years of smoking were compared between current smokers and 
ex-smokers and their correlation to the primary outcome measures, serum AMH and total AFC 
assessed. 
Paper IV: The primary outcome measure was serum AMH. We compared this in the five KID 
score categories. The secondary outcome measure was clinical pregnancy which was also 
compared in the five KID score categories. We also explored the relative impact of serum 
AMH and the number of retrieved oocytes on the pregnancy rate. 
4.1.8 Data collection 
We collected all data from medical notes and electronic patient records and entered them on 
secure, bespoke excel databases. 
4.1.9 Statistical considerations and sample size 
All statistical analyses for this thesis were performed using the Statistical Package for Social 
Sciences (SPSS V 20-26). Before analysis all data were assessed for descriptive statistics and 
normality of data distribution was checked. Skewed data were log transformed before analysis. 
The ANOVA test, Chi-squared test or a Kruskal-Wallis test were used for univariate analysis 
to assess differences between baseline variables and also outcome variables. A p-value of <0.05 
was considered to be statistically significant in all tests. Analysis of covariance (ANCOVA) 
was used to test for differences while controlling for confounding factors. Either a Pearson 
correlation (Paper II) test or a non-parametric correlation using Spearman rho (Paper I) was 
used to explore the relationships between variables of interest. In Paper IV, we performed a 
logistic regression analysis in order to explore the relative impact of serum AMH and the 
number of retrieved oocytes on the pregnancy rate. We used pregnancy as a binary outcome 
variable and serum AMH and number of oocytes as explanatory variables. 
For Paper IV, the sample size calculation was based upon the primary outcome of serum AMH. 
To detect an absolute decrease in AMH from 28.28 to 10.28 pmol/l with 80% power at a 5% 
significance level with an enrolment ratio of 0.5, we would require 96 participants (32 
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smokers/ex-smokers and 64 non-smokers). We planned to recruit approximately 100 
participants to compensate for dropout and loss to follow up. 
4.1.10 Ethical and regulatory approvals 
For Papers I and IV, ethics committee approval was not required as the study was based on 
routinely collected clinical data. The process of data extraction was consistent with the data 
protection rules. The study was approved by the Research and Development office of the 
Homerton University Hospital NHS Foundation Trust, London, UK. For Paper II, the study 
was approved by Health Research Authority and Health and Research Care Wales- Central 
Research Ethics Committee on 10/Apr/2019. (REC reference: 19/WA/0089). 
4.2 Evidence synthesis 
We conducted a systematic review and meta-analysis to study the effect of myo-inositol/di-
chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI. 
Standard methodology recommended by Cochrane was used (63). We first formulated the 
research question in terms of PICO (Participants, Intervention, Comparators and Outcomes). 
Participants Women with PCOS 
Intervention Treatment with either myo-inositol (MI), di-chiro inositol (DCI) or a 
combination of the two 
Comparators No treatment, folic acid, placebo or other treatment 
Outcomes  
Primary outcomes Serum AMH and AFC 
Secondary outcomes Number of retrieved oocytes, number of mature (metaphase II) 
oocytes, number of top grade embryos, pregnancy rate, live birth rate, 
risk of OHSS 
Table 4-3 Research question in terms of PICO 
We did a literature search to identify relevant studies which could answer the research question. 
Studies were identified by a search of electronic databases and hand searching. We formulated 
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the search strategy which included a combination of subject headings (MeSH/emtree) and text 
words relating to or describing the participants (polycystic ovary syndrome, PCOS, PCO 
polycystic ovar*) and intervention (inositol, myo inositol, di-chiro inositol). We searched the 
electronic databases MEDLINE, EMBASE, CENTRAL and CINAHL from inception till 
31/12/2017. We searched review articles and guidelines, reference lists of primary and review 
articles and trial registries for ongoing and unpublished studies. We included all published 
literature; randomised trials, non-randomised comparative studies and observational studies 
which were published as full-length manuscripts in the English language.  
After initial screening of abstracts, we obtained the full text of potentially suitable studies and 
assessed them for suitability. Two authors independently extracted data on a bespoke data 
sheet. We collected data for participants, intervention and outcomes and tabulated in 2x2 tables 
for dichotomous outcomes and 1x2 tables for continuous outcomes. We contacted authors of 
original articles when there was missing or unclear data in published manuscripts.  
We presented a narrative summary of results for all outcomes listed. We assessed included 
studies for clinical and methodological characteristics to determine if they were sufficiently 
similar to allow meta-analysis and a pooled estimate of individual outcomes to be studied. We 
analysed the data per participant for all outcomes except for the number of top grade embryos 
where the unit of analysis was embryos.  We presented the pooled estimates for outcomes as 
risk ratios (RR) for dichotomous variables and Mean Difference (MD)/Standardised Mean 
Difference (SMD) for continuous variables with 95% confidence intervals using the random 
effects model and inverse variance method. Statistical significance was assumed when p<0.05. 
Where sufficient data were available we planned subgroup analyses for the two different types 
of inositols: MI and DCI.  
We assessed the included studies for study quality and the risk of bias. As we included 
randomised and non-randomised studies we used different tools for assessment of the risk of 
bias. We used the Cochrane risk of bias assessment tool to evaluate randomised trials. We 
evaluated for bias in several domains such as sequence generation and allocation concealment, 
adequacy of blinding of participants, assessors and outcome assessors, completeness of 
outcome data, risk of selective reporting of outcomes and other potential sources of bias. We 
used the Risk Of Bias In Non-randomized Studies – of Interventions (ROBINS-I) assessment 
tool for evaluation of non-randomised studies.  
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We evaluated the overall quality of evidence for all outcomes using GRADE criteria (risk of 
bias, consistency of effect, imprecision, indirectness and publication bias). We used the 
Guideline Development Tool software to prepare a summary of findings of the quality of 
evidence. We reported the judgements about strength of recommendation (high, moderate. low 
or very low) based on these findings.   
We prospectively registered the systematic review on the International Prospective Register of 
Systematic Reviews (PROSPERO) (Registration:  CRD42017082275) 
5 Results 
5.1 Paper I: PCOS phenotypes and AMH 
262 women were recruited to the study. 199 had PCOS and 63 had isolated PCOM. These were 
divided based on their phenotype into five groups as below 
PCOS A (OA+ HA+ PCOM): 91 
PCOS B (OA+HA): 7 
PCOS C (HA+PCOM): 59 
PCOS D (OA+PCOM): 42 
PCOM (PCOM): 63 
The AMH/AFC ratios as a marker of per follicle AMH production was compared in the five 
groups. The median AMH/AFC ratios in PCOS A, PCOS D, PCOS C and PCOM were 1.5, 
1.6, 1.2 and 1.1 respectively.  
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Table 5-1 Median AMH/AFC ration in various phenotypes of PCOS and PCOM (based on 
data from Paper 1) 
 
Univariate analysis showed AMH/AFC ratios in the anovulatory phenotypes A and D to be 
significantly higher than in women with isolated PCOM (p=0.004 and 0.002 respectively). 
There was no significant difference in the AMH/AFC ratios between the ovulatory PCOS 
phenotype C and isolated PCOM (p=0.59). These findings remained unchanged after 
accounting for differences in age and BMI in a multivariate analysis.  
Non-parametric bivariate correlation using Spearman rho showed a significant but weak 
positive correlation between the AMH/AFC ratio and the FAI (r =0.274, n=249, p=0.001) and 
LH (r =0.280, n= 249, p<0.001). No correlation was seen between the AMH/AFC ratio and 
insulin (r =0.154, n=249, p=0.123).   
5.2 Paper II: Smoking and ovarian reserve markers 
101 women were recruited to the study from July 2019 to February 2020. Based on a self-
reported smoking history women were classified into three comparison groups: current 
smokers, ex-smokers and never smokers. The baseline clinical characteristics of the 
participants such as age, BMI, ethnicity, history of ovarian surgery, infertility diagnosis and 
diagnosis of PCOS were compared in the three groups. There were no significant differences 
seen in the baseline variables amongst the groups. 
Pack years of smoking, quantifying exposure to cigarette smoking, were not significantly 





PCOS A PCOS D PCOS C PCOM
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were significantly different amongst current, ex- and never smokers (F(2,97) = 33.32, 
p<0.0001). Urine cotinine levels were also significantly higher in current smokers as compared 
to ex-smokers and never smokers. (p< 0.001). Current smokers reported to be more exposed to 
passive smoking (75%, 9/12) as compared to ex-smokers (20%, 5/25) and never smokers (25%, 
16/64) (p=0.001). 
No significant difference was observed amongst current, ex- and never smokers either for 
serum AMH (F(2,91) = 1.19, p=0.309) or total AFC (F(2,81) = 0.403, p= 0.670). When 
comparing baseline variables, age showed borderline non-significance between the groups 
(p=0.057). Hence, we performed an analysis of covariance (ANCOVA) to explore the impact 
of smoking status on serum AMH using age as a covariate. No significant difference was 
demonstrated among the three groups (F(2,90) = 0.398, p = 0.673). 
No significant correlation was demonstrated between the pack years of smoking and serum 
AMH (r= -0.212, n=23, p=0.166) or total AFC (r= -0.276, n=19, p=0.126). No significant 
correlation was found between breath CO and serum AMH (r= 0.082, n=94, p=0.216) or total 
AFC (r= 0.096, n=83, p=0.195). Similarly, no significant correlation was found between urine 
cotinine levels and serum AMH (r= 0.146, n=83, p=0.095) or total AFC (r= -0.027, n=77, 
p=0.386). 
5.3 Paper III: Systematic review on inositols and ovarian reserve 
18 studies were selected for the review.  Seven studies assessed changes in either AMH or AFC 
or both. Twelve studies evaluated outcomes following IVF/ICSI treatment. One study 
evaluated both categories of outcomes.  
5.3.1 Included studies: 
Of the studies assessing changes in AMH and /or AFC, only two of the seven studies were 
randomised controlled trials and five were non-randomised studies. All studies were single 
centre studies. A total of 415 women were recruited to these seven studies. A majority of the 
studies, five of the seven, were conducted in Italy. Although all participants in the included 
studies were diagnosed with PCOS, there were varying restrictions in the inclusion criteria 
based on age, body mass index and insulin resistance in some studies. We have included a 
study (Pkhaladze 2017(131)) which recruited participants between 13-19 years of age based 
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on a consensus opinion from the international paediatric subspecialty societies. There was a 
wide variation in the preparation of inositol used (MI and DCI), doses administered (ranging 
from 1 gm to 4 gm daily) and duration of administration (between 12 weeks to 6 months) with 
no explanations for these variations. Four studies assessed the effect on serum AMH and three 
assessed its effect on AFC. 
10 of the 12 studies assessing reproductive outcomes after IVF/ICSI were RCTs and only two 
were non-randomised studies. All studies were single centre studies. Again, most of the studies 
were conducted in Italy (10 of the 12). A total of 1225 women, all with a diagnosis of PCOS 
were included in the 12 trials. Some studies restricted inclusion of participants based on age, 
body mass index and insulin resistance. Heterogeneity in the preparation of inositols used, dose 
(1-4 gm /300-1200 mg daily) and duration of treatment (2 weeks to ongoing treatment) were 
observed. Details are described in the manuscript. 
5.3.2 Risk of bias and quality of evidence in included studies 
Of the randomised trials, 75% of trials were at low risk for selection bias for random sequence 
generation but only 17% were considered low risk for allocation concealment. Similarly, only 
25% of studies were considered at low risk of performance bias due to blinding. The risk of 
attrition bias due to incomplete outcome data was low in 42% of studies. None of the trials 
were considered at low risk of reporting bias.  
All the non-randomised studies were considered at a high risk of selection bias due to the 
presence of confounders or inclusion of participants into the study. 83% were low risk for bias 
in classification of interventions and 67% were at low risk of bias due to missing data. 50% of 
studies did not provide information on nonconformities in the planned interventions and all of 
the studies were at high risk of reporting bias.  
The quality of evidence contributing to the review was considered to be very low across most 
domains. These included inconsistency, indirectness, imprecision and a high risk of bias.  
5.3.3 Synthesis of the results: 
5.3.3.1 Primary Outcomes: 
Anti-Mullerian Hormone 
The studies assessing change in serum AMH before and after treatment with inositols showed 
significant clinical and methodological heterogeneity. Hence it was deemed unsuitable to 
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include these results for a meta-analysis. Five studies with 172 participants were included in 
this section of the review. The results for a standardised mean difference in levels of serum 
AMH before and after treatment for the five individual studies showed was no consistent 
direction or size of effect. This is graphically represented in the published manuscript.  
Antral follicle count 
We did not perform a meta-analysis for the studies which assessed changes in the antral follicle 
counts after treatment with inositols due to clinical and methodological heterogeneity of the 
included studies. Four studies with 143 participants were included in this section of the review. 
The SMD show a high heterogeneity in effect size for AFC.  This is graphically represented in 
the published manuscript.  
Overall, the review is unable to demonstrate a clear change in AMH or AFC values following 
treatment with inositol. 
5.3.3.2 Secondary Outcomes: 
Number of retrieved oocytes 
Eleven studies reported the number of oocytes retrieved. Seven RCTs comprising 722 
participants were included in the meta-analysis. We were unable to find a statistically 
significant difference between the intervention and control arms (MD -0.39, 95% CI -1.11, 
0.33). Similar results were seen for a subgroup analysis for MI (MD -0.76 95% CI -2.04, 0.52) 
and DCI (MD -0.18 95% CI -1.11,0.74).  
Data from two studies (Ciotta 2011(132) and Lesoine 2016(133))could not be included in the 
meta-analysis as data were presented in an unsuitable format suitable for meta-analysis. These 
studies reported contradictory results. Ciotta 2011 reported a significantly higher number of 
oocytes following treatment with MI as compared to control (p<0.05) in contrast to Lesoine 
2016 who reported a higher number of oocytes in the control group as compared to the MI 
group. Alviggi 2016 (134) in a non-randomised study reported no significant difference 
between the MI and control groups (p=0.23) similar to Unfer 2011 (135) who compared 
treatment with MI to DCI.  
Number of metaphase II oocytes 
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10 studies reported on the number of metaphase II oocytes retrieved. Three RCTs with 207 
participants were included in the meta-analysis. No statistically significant difference was seen 
between the intervention and control arms (MD 0.29, 95% CI -0.83, 1.40). Similar results were 
seen for a subgroup analysis for MI (MD -0.32 95%CI -1.49, 0.86). Seven other trials could 
not be included in the meta-analysis as data from these studies were in an unsuitable format for 
inclusion in the meta-analysis.  They reported contradictory results with no consistent direction 
of effect. Piomboni 2014 (136) reported significantly higher number of MII oocytes, with a 
moderate effect size, following treatment with DCI as compared to control (MD 1.30 95%CI 
0.15, 2.45) in contrast to Isabella 2012 (137) who reported a significant decrease in the number 
of MII oocytes following treatment with DCI as compared to control. Artini 2013 (138) 
reported a significant increase in the percentage of top quality oocytes in the group treated with 
MI as compared to control (p<0.05). Pacchiarotti 2016 (139) and Ciotta 2011 reported no 
significant differences between the groups. The results from Lesoine 2016 are unclear. Alviggi 
2016 in a non-randomised study reported a significant increase in the number of MII oocytes 
following treatment with MI as compared to control (p=0.03). Unfer 2011 compared treatment 
with MI to DCI and reported a significant increase in the number of MII oocytes following 
treatment with MI as compared to DCI (p<0.05). 
Number of top-grade embryos 
Four RCTs comprising 957 participants and reporting number of top-grade embryos were 
included in the meta-analysis. We were unable to find a significant difference between the 
groups (RR 1.02, 95% CI 0.93-1.12). Four studies reporting this outcome had data in an 
unsuitable format for inclusion in the meta-analysis. These studies did not show a consistent 
direction of effect. Pacchiarotti (2016) reported no significant difference in the number of top-
grade embryos between the MI and control groups. Isabella (2012) reported a significant 
decrease in the number of top-grade embryos following treatment with DCI (p<0.01) in 
contrast to Lesoine (2016) who reported a significantly higher number of top-grade embryos 
following treatment with MI as compared to control (p<0.05). Unfer (2011) reported a 
significantly higher number of top-grade embryos following treatment with MI as compared to 
treatment with DCI (p<0.01). 
Clinical pregnancy rate 
Three RCTs comprising 488 participants and reporting clinical pregnancy rates were included 
in the meta-analysis. We were unable to find a significant difference between the groups (RR 
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1.16 95% CI 0.87, 1.53). Three studies (Schillaci 2012 (140), Alviggi 2016 and Wdowiak 2016 
(141)) did not detail if the pregnancies were biochemical or clinical and were hence not 
included in the meta-analysis. These studies reported no significant differences between the 
groups. When comparing treatment with MI to DCI Unfer (2011) reported no significant 
difference in clinical pregnancy rates between the two groups. 
Live birth rate 
Only one trial (Artini 2013) reported live birth rate. This reported a significant improvement 
following treatment with MI compared to placebo (p<0.05). 
Risk of cycle cancellation due to the risk of OHSS 
Six studies reporting cycle cancellations due to the risk of ovarian hyperstimulation syndrome 
were included in the meta-analysis. We were unable to demonstrate a significant difference 
between groups (RR 0.73, 95% CI 0.39, 1.37).  Similar results were seen for a subgroup 
analysis for MI (RR 0.70 95% CI 0.34, 1.42) and DCI (RR 0.85, 95% CI 0.22-3.29).  
5.4 Paper IV: Serum AMH and embryo quality 
198 participants and 304 embryos were included for analysis. Embryos were categorised into 
five groups based on the KID scores. For the primary outcome, serum AMH, univariate 
analysis demonstrated no significant differences between the five KID score categories (F 
(4,293) = 1.769, p = 0.135). Univariate analysis however showed significant differences in age 
and method of insemination for the different KID score categories (p=0.049 and p=0.033 
respectively). Hence and ANCOVA test was done to test for differences in AMH levels among 
KID scores while controlling for significant confounding variables. This showed no significant 
differences (p = 0.305). 
There was a significant difference for the secondary outcome of pregnancy rate between the 
KID score categories. Serum AMH however did not have a significant impact on pregnancy 
rates.  
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6 Discussion 
6.1 Main findings 
Paper I evaluated the per follicle AMH production in the various phenotypes of PCOS and 
isolated PCOM. The study showed a significantly increased per follicle AMH production in 
the anovulatory phenotypes of PCOS as compared to women with isolated PCOM. No 
significant difference was found between the ovulatory phenotype of PCOS and isolated 
PCOM. The study was unable to show a substantial role for androgens, insulin or LH in the 
increased per follicle AMH production.  
Paper II examined the association between cigarette smoking and ovarian reserve parameters. 
We did not find a statistically significant difference in either serum AMH or AFC between 
current, ex and never smokers in our study population. By demonstrating significant 
differences in breath CO and urine cotinine levels among the groups we confirmed that self-
reported smoking correlates well with quantitatively measured markers of smoking. We did 
not find a significant correlation between the pack years smoked and serum AMH and AFC. 
We did not find a significant association between biomarkers of smoking and biomarkers of 
ovarian reserve. 
Paper III assessed the impact of pharmacological intervention with the insulin sensitiser, 
inositol, on ovarian reserve markers using evidence synthesis. Our systematic review was 
unable to demonstrate a consistent direction or size of effect for a change in serum AMH or 
AFC after treatment with inositols. Thus, we are unable to provide adequate evidence for a 
quantitative change in the antral follicle pool subsequent to treatment with inositols. We were 
unable to perform a meta-analysis for the primary outcome due to substantial clinical and 
methodological heterogeneity of the published studies. No significant differences between the 
inositol and control groups were seen for any of the secondary outcomes of the review. These 
included the number of retrieved oocytes, number of metaphase II oocytes, number of top-
grade embryos, pregnancy rates and the rates of cycle cancellation due to the risk of OHSS.  
Paper IV assessed the association between ovarian reserve and embryo quality in women 
undergoing IVF/ICSI treatment. There was no significant association between baseline serum 
AMH at the start of IVF treatment and embryo quality assessed by time lapse imaging. Serum 
AMH positively correlated to pregnancy rates due to the increased number of oocytes retrieved 
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during the treatment rather than an impact of serum AMH on embryo quality. Embryo quality 
showed a significant positive association with clinical pregnancy rates. These results remain 
important for counselling women who plan to start IVF treatment. 
6.2 Interpretation of results 
For Paper I, the finding of a greater per follicle production of AMH in anovulatory PCOS 
supports the hypothesis for a role for AMH in the mechanism of ovulatory dysfunction. High 
intra-follicular concentrations of AMH due to an increased per follicle production are 
postulated to cause a greater inhibition of FSH induced aromatase expression. This results in a 
heightened inhibitory response to follicular maturation and ovulation resulting in the ovulatory 
dysfunction associated with PCOS.  
The mechanism for this increased per follicle AMH production remains unknown. Although 
the FAI showed a weak significant correlation with the AMH/AFC ratio other indicators were 
unable to support a role for androgens. The high per follicle AMH production was not different 
in the androgenic (A) and non-androgenic (D) phenotypes. Also, it  was similar in the 
androgenic phenotype C and isolated PCOM which is normo-androgenic. It may be suggested 
that the positive correlation of serum AMH and androgens (142) may be due to increased 
folliculogenesis rather than an increased per follicle production. LH levels were not 
significantly different amongst PCOS phenotypes and LH showed only a weak correlation with 
the AMH/AFC ratio. It is unclear if the positive correlation between serum AMH and LH in 
women with PCOS (36) is due to an independent action of LH or indirectly through the 
androgen pathway. Similarly, our study indicate a limited role insulin as a factor leading to an 
increased per follicle AMH production. The correlation of insulin with serum AMH is likely 
to be similar to androgens as it may increase serum AMH through androgen mediated 
folliculogenesis rather than increasing the amount of AMH produced per follicle. The absence 
of a substantial association between androgens, LH and insulin and the per follicle AMH 
production, points to an intrinsic granulosa cell dysfunction. A recent meta-analysis of genome 
wide association studies suggests a similar genetic architecture for phenotypically distinct 
subtypes of PCOS (143). 
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For Paper II, although biological plausibility exists for the effect of smoking on ovarian reserve 
and ovarian ageing, these effects were not evident in our study population of younger women 
based on serum AMH and AFC. Animal studies have suggested adverse effects of cigarette 
smoking on ovarian reserve (83, 84). Several mechanisms have been postulated, which may 
affect quality, quantity or both. Gannon et al (2012),(85) hypothesised a mechanism of direct 
toxicity to ovarian follicles resulting in an accelerated follicle loss. An indirect effect on ovarian 
follicle numbers has been suggested through an action on the hypothalamic pituitary axis (144). 
The discordance of our results with some previously published studies may be attributed to 
several reasons. The natural decline of ovarian reserve with age does not follow a linear 
function but shows a rapid decline with increasing age (41). It has also been suggested that 
ovarian follicles may differ in susceptibility to the effects of smoking at different ages with 
older oocytes being more susceptible to negative effects of smoking. Hence, the effects may 
not evident in our study population of younger women. The effect of smoking may be dose 
related. The pack years of smoking in our study population was relatively low at 2.13 pack 
years. It is possible that the deleterious effects are evident only at higher levels of smoking 
exposure or lower levels of smoking may be associated with smaller magnitude of reduction in 
ovarian reserve markers. Although it may be possible to demonstrate such small differences 
with a larger sample size, the clinical implications of such findings would be questionable. 
Serum AMH and AFC are largely used in young women in the context of fertility treatment, 
to predict ovarian response to treatment and pregnancy rates. Hence in younger women seeking 
fertility treatment, a clinically relevant decrease in ovarian reserve may be considered one 
which significantly reduces the probability of the most important outcome for this group of 
women; the pregnancy rate. Significantly lower pregnancy rates have been reported in the 
lowest quartile of AMH below 10.28 pmol/l (111).  Pregnancy rates in women with serum 
AMH in the upper three quartiles are not statistically different from each other (111).  The 
absence of an association between smoking and serum AMH and AFC also argues for a 
mechanism against follicular atresia. This is strengthened by the finding of no association 
between ex-smokers and lower AMH values in our study and also in other studies such as 
Dolleman et al (2013)(53).  
For Paper III, based on the included evidence we are unable to recommend treatment with 
inositols with the aim of changing the antral follicle pool/ovarian reserve markers or improving 
outcomes following IVF/ICSI treatment. Although ovarian reserve markers are not endpoint 
clinical outcomes, they remain important for several reasons. Firstly, the antral follicle pool is 
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dynamic and as discussed before is amenable to change due to the influence of external factors. 
Inspite of a normal primordial follicle pool, serum AMH and AFC are diminished in states 
where ovarian steroidogenesis and subsequent folliculogenesis has been suppressed such as 
long term treatment with oral contraceptives, GnRH agonists or states of hypothalamic 
amenorrhoea. Similarly, the antral follicle pool is greater in women with PCOS. Initial 
assessment and subsequent alteration of the antral follicle pool may result in improved 
reproductive outcomes for these women.  
Inositols have shown to significantly reduce androgen levels in women with PCOS (145). 
Hence, due to their biological plausibility to alter ovarian folliculogenesis, changes in serum 
AMH and AFC following treatment with inositols would support the mechanism of action of 
inositols through the insulin-androgen-folliculogenesis pathway. 
Lastly, knowledge of changes to the antral follicle pool would help to plan fertility treatment 
and IVF/ICSI protocols. Reduction in the quantitative antral follicle pool would reduce the risk 
of OHSS which remains an important iatrogenic complication of IVF in women with PCOS.  
From Paper IV, our results demonstrate that serum AMH and AFC remain excellent markers 
of quantitative ovarian reserve but show no association with the quality of embryos. Although 
pregnancy rates may relate positively with serum AMH and AFC, this effect is indirect through 
the increased number of oocytes retrieved and hence the possibility of better quality of embryos 
being available for transfer. These results remain very important for counselling women 
embarking on fertility treatment.  
6.3 Comparison with previous literature 
For Paper I, the findings of our study agree with those of Alebic et al (2015)(146). Their in-
vivo study also analysed the per follicle AMH production in women with PCOS and PCOM 
and found a higher per follicle AMH production in the anovulatory phenotypes of PCOS. In 
vitro studies show agreement with our findings (28).  
For Paper II, our results agree with those of Bressler et al (2016) (55). They were unable to 
demonstrate an association between smoking exposure and serum AMH in a population based 
cross-sectional analysis. The age of their study population was women aged 23-35 years which 
is similar to that of our study. However, exposure ascertainment was done using only a self-
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reported questionnaire. Similarly, Kline et al (2016) reported no association between AMH and 
smoking in a cross-sectional study using self-reported smoking to ascertain exposure. 
Dolleman et al (2013) in a large population based study reported lower serum AMH in current 
smokers (but not in ex-smokers) as compared to never smokers. The study population was 
however significantly older (mean 37.3, SD 9.2) than our study population, which may explain 
a difference in the results. It has been suggested that the increase in follicular decline may be 
accelerated and more evident with advancing age(144). Also, the smoking exposure in pack 
years was higher in this population (mean 10.2, SD 9.1) as compared to our study (median 2.13 
(IQR 0.59-3.48)) which could account for the differences. Dolleman et al (2013), reported a 
threshold after which the linear association of pack years and serum AMH was significant. 
They reported this at 10 pack years of smoking below which there was no significant 
association with serum AMH. Hence, these results could be considered to be in agreement with 
our study. 
For Paper III, to our knowledge, this is the first review to assess the effect of inositols on 
ovarian reserve markers. Other systematic reviews have reported the effects of inositols on 
outcomes following IVF/ICSI treatment (147-150).  The first of these reviews by Unfer et al 
(2016)(147) included only five studies and reported an improvement in oocyte and embryo 
quality. The findings of this review are in disagreement with those of our review. The review 
however was a narrative systematic review rather than a meta-analysis. The discordant results 
may be due to positive outcomes in earlier studies included in this review, in contrast to 
contradictory findings in some recent studies included in our review resulting in a pooled 
estimate showing no significant difference in outcomes. The review does not discuss the quality 
of evidence presented or the risk of bias and there may be concerns about publication bias. 
Similar positive outcomes were reported by Gateva et al (2018) (148). Being a narrative review 
rather than a systematic review and being published by the same group of authors lends it to 
similar criticisms. A more recent review by Mendoza et al (2017)(149) reports findings broadly 
in agreement with our review. However, the findings of our review may be considered more 
robust as we have added 4 more studies with 206 participants. We have reported on ovarian 
reserve markers which was not considered and discussed by Mendoza et al (2017). We were 
also the first to review the effect of inositols on the risk of OHSS in IVF/ICSI treatment and 
provide a pooled effect estimate. This is an important safety outcome for any trial  intervention 
on women with PCOS who are at a greater risk of OHSS following IVF/ICSI. Our review has 
also provided a formal and objective assessment of the quality of evidence included. Morley et 
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al (2017), in a Cochrane review include a section on the effect of inositols in women with 
PCOS (150). Due to very stringent inclusion criteria only two studies and none of the outcomes 
of this review are included. Similarly, a very recent Cochrane review discusses the effects of 
inositols on outcomes following IVF/ICSI treatment (151). The two outcomes investigated by 
this review (live birth and clinical pregnancy) are in broad agreement with those reported by 
our review. 
For Paper IV, our results are in agreement with those of Smeenk et al (2007), which 
demonstrated a positive correlation between serum AMH and the number of oocytes and 
embryos but was unable to show a predictive capacity with respect to embryo quality. Embryo 
grading was done by morphological assessment on day 3 of embryo culture (152). In a study 
by Fong et al (2008), participants were allocated to receive either standard stimulation or mild 
stimulation. In the standard stimulation group there was no correlation seen between serum 
AMH at start of treatment and embryo morphology. These participants also had pre-
implantation genetic screening of embryos. There was no correlation seen between baseline 
serum AMH and aneuploidy rate (153). This supports the results of our study. When serum 
AMH was measured on the day of hCG trigger, a significant decrease in serum AMH was seen 
in the standard stimulation group but not the mild stimulation group. In the mild stimulation 
group, baseline serum AMH showed a positive correlation with embryo quality. The authors 
have hypothesised this to be due to the mild stimulation protocol, which allows recruitment of 
only the most FSH sensitive follicles which constitute the better quality oocytes. However, no 
correlation between serum AMH and aneuploidy rates were demonstrated even in the mild 
stimulation group. Although invasive, PGS is a more objective assessment than morphology 
alone and hence in that sense, the results of this study would agree with our findings. Silberstein 
et al (2006)(154) reported similar results to Fong et al (2008). Higher serum AMH 
concentrations on the day of hCG trigger, with levels greater than 2.7 ng/ml were associated 
with better embryo quality. Some studies have measured and reported follicular fluid AMH 
and its positive correlation to embryo quality (155). The pragmatic value of the measurement 
of serum AMH on the day of hCG or follicular fluid AMH may be considered academic as it 
is impossible to change management, delay or stop treatment at this point for an individual 
participant. 
More recent studies confirm the findings of our study. Morin et al (2018), reported results 
agreeing with our findings. In women < 38 years, no differences were seen in blastulation rates, 
aneuploidy rates and live birth rates despite differences in baseline serum AMH levels (156). 
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A more recent study which assessed morphokinetic parameters in normal and low responders 
based on baseline serum AMH levels found no difference in embryo quality between the two 
groups (157).  
6.4 Strengths and limitations 
We have used a cross-sectional study design for all the three primary studies. As none of these 
studies had an active intervention, treatment or deliberate exposure and aimed to identify an 
association between two or more variables of interest, we considered this to be the most suitable 
design to answer the research questions. 
For Paper I, a cross-sectional design allowed identification of an association between PCOS 
phenotype and the per follicle AMH production. Although unable to infer causality, as both 
variables (exposure and outcome) would be assessed at the same time point, it could be useful 
to support a hypothesis for causation of ovulatory dysfunction based on biological plausibility. 
 For Paper II, which aimed to assess the impact of smoking on ovarian reserve markers, a cross-
sectional design was suitable to identify this association, especially as the exposure (smoking) 
could not be deliberate. Again, although a causal relationship cannot be established, 
associations in different smoking categories such as current and ex-smokers could support 
hypotheses for causality. A cross-sectional design was also appropriate for Paper IV to 
understand the association between ovarian reserve markers and embryo quality. However, 
with this design it was not possible to derive a causal relationship between the two.  
Bias is inherent to all observational study designs. Hence, we have carefully considered factors 
which may introduce bias and adjusted for these as far as possible in either in the design or 
analysis phases of the work packages. 
In the design phase we carefully selected the inclusion criteria appropriate for each study. For 
Paper I on women with PCOS, we included all eligible women with PCOS and isolated PCOM 
in the defined study period. As individual patient consent was not required this minimised 
volunteer bias. Using well defined objective inclusion criteria allowed appropriate 
characterisation of the participant groups. The women with PCOS were in the reproductive age 
group and came from diverse social and ethnic backgrounds making the study group 
representative of the population to be studied. For Paper II on smoking and ovarian reserve, 
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the participants included an unselected population of women attending the clinic for various 
investigations and treatments. There were wide variations in the baseline characteristics of 
participants such as ethnicity, cause of infertility and diagnosis. By using a wide-ranging 
unselected population of women, we have attempted to improve the generalisability of the 
results. Age remains a major determinant of ovarian reserve. We have included only women 
35 years and younger to reduce bias due to the impact of advancing age. The participants 
included only sub-fertile women with a limited range of BMI and age. This is because fertility 
treatment within the UK and funded by the National Health Service is restricted by limits on 
age and BMI. Therefore, caution should be exercised when extrapolating these results to other 
populations. For Paper IV related to embryo quality and ovarian reserve in women undergoing 
IVF, we attempted to reduce selection bias using wide inclusion criteria and hence consider the 
population studied to be representative of the wider population of women undergoing IVF/ICSI 
treatment. As no systematic criteria were used to place individual participant embryos in either 
standard incubators or time lapse incubators, it is unlikely that these populations would be 
sufficiently different to introduce bias and affect results. Volunteer bias was minimal as 
informed consent of individual participants was not required and all eligible participants were 
included.  
As discussed earlier, all women included for the work packages in the thesis were patients at 
the fertility clinic. Hence, caution should be exercised when extrapolating the results to the 
general population. However, as the research questions were related to fertility and fertility 
treatment, we agreed that this would be an appropriate population for conducting the studies.  
We have collected data for confounding variables which may affect the direction and strength 
of the associations assessed and accounted for these during statistical analysis for all our 
studies. Ascertainment of all our exposures and outcome measures were well-defined, 
objective and validated, thus reducing observer bias.  
Serum AMH and AFC were assessed with standardised measurements to reduce variability. 
All hormonal measurements were conducted using standardised assays. Androgens were 
measured using mass spectrometry (MS) coupled with liquid chromatography (LC) as 
recommended by international guidelines (128). 
We have used breath CO and urine cotinine as biomarkers of smoking to validate self -reported 
smoking history. This is in agreement with previously reported studies. Marrone et al (2010), 
report significantly higher breath CO and cotinine levels in smokers compared with non-
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smokers (P<0.001), with 100% specificity and sensitivity at a concentration of 5ppm (158). 
Similarly, MacLaren et al (2010), reported a strong agreement between self-reported smoking 
and breath CO levels with a sensitivity of  96% and specificity of 93.3% using a cut off of 
7ppm (159).  
A major strength of our study on smoking is that we used a comprehensive and detailed self-
reported questionnaire to assess smoking exposure, which allowed estimation of lifetime 
smoking exposure in terms of pack years and also accounted for passive smoking. Furthermore, 
we also used breath CO and urine cotinine concentrations to validate our study groups. The 
CO breath test shows the amount of CO in the breath (ppm), as an indirect, non-invasive 
measure of blood carboxyhaemoglobin (%COHb). CO leaves the body rapidly and the half-
life is about 5 hours. Within 24 to 48 hours of not smoking, smokers will be at non-smoker 
levels. Cotinine is the predominant metabolite of nicotine. It has a half-life of 20 hours and is 
detectable for up to one week after the use of tobacco. This is useful to identify smokers who 
have abstained from smoking for several hours. Our study was powered only to detect 
differences in ovarian markers of relatively large magnitude that we considered to have a 
clinical significance in the management of young women seeking fertility treatment.   
However, a much larger sample size would be required to detect statistically significant 
differences of smaller magnitude which may be relevant to different study populations and 
research questions.  
The use of the time lapse incubators for embryo grading and assessment may be considered a 
major strength of this study. The use of this system, which  provides greater detail and allow a 
more objective and reproducible assessment of embryo quality has eliminated 
ascertainment/observer bias. Smoking status for this study was the only self-reported variable 
which may have been subject to reporting bias. This however was unlikely to affect the results 
as the distribution of smokers and non-smokers was not significantly different in the compared 
groups. For women with a double embryo transfer the values for serum AMH were duplicated 
during analysis. This may be considered a limitation. However, including only those women 
with a single embryo transfer would have considerably reduced the number of women in the 
dataset as only 25-30 % of all transfers are single embryo transfers in addition to introducing a 
selection bias. 
For our systematic review we have used standard Cochrane methodology to ensure quality 
assurance. To minimise the impact of reporting bias, we have aimed to identify all eligible 
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studies for inclusion in the review by conducting a thorough search of the published literature. 
We evaluated studies for prospective trial registration and availability of a trial protocol to 
assess in-study reporting bias.  We have included of all types of published literature rather than 
only randomised controlled trials for the review. Although it may be argued that inclusion of 
non-randomised studies has the potential to introduce bias and confounding, we have included 
these with the aim of increasing external validity and to provide a comprehensive review. 
Although RCTs may be generally accepted to safeguard against a biased estimate of the 
treatment effect, literature reports that the direction and magnitude of the effect may not differ 
due to inclusion of non-randomised studies in many cases (160). Where information was 
missing, we have attempted to contact the study authors to seek further information. Some 
information was received from authors but as we were unable to get information from others 
we were unable to include data from these studies. 
Specific problems with study design, especially heterogeneity of populations and intervention 
were identified. The quality of evidence included in this review was assessed to be very low. 
This related to the risk of bias, imprecision, inconsistency, indirectness and publication bias. 
Major concerns regarding study design, prospective trial registration, sample sizes, sample size 
calculations and blinding were noted. All these may be considered major limitations of the 
evidence synthesized. 
7 Future research 
Our study on the per follicle AMH production supports the hypothesis for the mechanism of 
anovulation in PCOS. The correlation between the magnitude of higher per follicle AMH and 
the degree of increased FSH resistance remains unclear. Several other variables/factors in 
addition to an increased per follicle AMH production may impact the degree of FSH sensitivity 
and response to ovulation induction treatments. Cluster analysis of large cohorts utilising 
anthropometric, ultrasound and biochemical markers along with response to ovulation 
induction treatments will identify of specific subtypes allowing a more targeted approach to 
treatment. 
Inositols are commonly prescribed by clinicians and patients themselves without good 
evidence about their benefit. Our review highlights the need for further studies with robust 
design and adequate sample size are needed to provide a definitive answer to the question. An 
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ideal study should aim to include an appropriate PCOS population with selection based on 
criteria such as BMI and insulin resistance. The dose and duration of effective treatment should 
be sought in appropriately designed dose-response studies. The two inositol isoforms need to 
be studied separately and in different dose combinations. 
8 Conclusions 
The results of our study show an association between AMH and ovulatory dysfunction, with a 
greater per follicle AMH production  in anovulatory phenotypes as compared to isolated 
asymptomatic PCOM. This supports the hypothesis for a patho-physiological role for AMH in 
women with anovulatory PCOS where the physiological inhibitory role of AMH appears to be 
heightened. The absence of an association between androgens, LH and insulin to the per follicle 
AMH production, points to an intrinsic granulosa cell dysfunction. 
Exposure to cigarette smoking in women £ 35 years seeking fertility treatment did not 
significantly change the antral follicle pool and no significant association was found between 
biomarkers of smoking or lifetime smoking exposure and biomarkers of ovarian reserve. 
A systematic review of published literature did not provide adequate evidence for a change in 
ovarian reserve following the use of inositols in women with PCOS and to support the use of 
inositols as a pre-treatment in women with PCOS undergoing IVF/ICSI treatment to improve 
safety of the procedure or reproductive outcomes. The results of our study show no significant 
association between serum AMH and embryo quality in women undergoing IVF/ICSI 
treatment. Their positive association with improved pregnancy outcomes following IVF/ICSI 
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Abstract page 22 
Effect of cigarette smoking on serum anti-Mullerian hormone and antral follicle count in 23 
women seeking fertility treatment. 24 
P Bhide, E Timlick, A Kulkarni, A Gudi, A Shah, R Homburg, G Acharya 25 
Objective 26 
The relationship between smoking and markers of ovarian reserve is inconclusive. The 27 
primary objective of our study was to assess the effect of cigarette smoking on the 28 
quantitative ovarian reserve parameters, serum anti-Mullerian hormone (AMH) and antral 29 
follicle count (AFC) in women seeking fertility treatment. Our secondary aims were to 30 
validate self-reported smoking behaviour using biomarkers and evaluate the association 31 
between biomarkers of ovarian reverse (serum AMH and AFC) with biomarkers of smoking 32 
exposure (i.e. breath carbon monoxide (CO)  and urine cotinine levels).  33 
Study Design  34 
We conducted a single-centre, cross-sectional study in women  35 years and assessed the 35 
association between markers of cigarette smoking (self-reported smoking history, breath CO 36 
and urine cotinine) and serum AMH and AFC. 37 
Results 38 
Significant differences were found amongst current smokers, ex-smokers and never smokers 39 
for breath CO (F(2,97)=33.32, p< 0.0001) and urine cotinine levels (p< 0.001). However, no 40 
significant differences were found  either for serum AMH (F(2,91)=1.19, p=0.309) or total 41 
AFC (F(2,81)=0.403, p=0.670) among these three groups. There was no significant 42 




































































or total AFC (r=-0.276, n=19, p=0.126). No significant correlation was demonstrated 44 
between breath CO and serum AMH (r=0.082, n=94, p=0.216) or total AFC (r=0.096, n=83, 45 
p=0.195). Similarly, no significant correlation was demonstrated between urine cotinine 46 
levels and serum AMH (r=0.146, n=83, p=0.095) or total AFC (r=-0.027, n=77, p=0.386).  47 
Conclusion 48 
We did not find a statistically significant difference in quantitative ovarian reserve markers 49 
between current, ex- and never smokers in our study population.  We confirmed that self-50 
reported smoking correlates well with quantitatively  measured markers of smoking, 51 
validating the comparison groups based on self-reported smoking history to ensure a valid 52 
comparison of outcome measures. There was no significant association between biomarkers 53 
of smoking and biomarkers of ovarian reserve. We were also unable to demonstrate a 54 
correlation between the lifetime smoking exposure and ovarian reserve. 55 
Keywords 56 
Ovarian reserve, anti-Mullerian hormone, antral follicle count, smoking, cotinine, carbon 57 
monoxide 58 
 59 




































































1 Introduction 61 
Anti-Mullerian hormone (AMH) and antral follicle count (AFC) are well established 62 
biomarkers of ovarian reserve, commonly used in the context of fertility treatment(1, 2). 63 
Estimation of the size of the primordial follicle pool is difficult and impractical for routine 64 
clinical application as there is no known biochemical marker for estimating the number of 65 
primordial follicles, and their small size makes in-vivo imaging with sufficient resolution 66 
impossible using currently available technology. A subsection of the true ovarian reserve is 67 
the pool of pre-antral and antral follicles which are responsive to pituitary gonadotropins 68 
and are clinically relevant for menstruation, ovulation and fertility. The currently available 69 
biomarkers, AMH and AFC, measure the antral follicle pool. AMH is expressed exclusively by 70 
the granulosa cells of pre-antral and small antral follicles in the ovary and hence an excellent 71 
quantitative marker of the ovarian reserve(3). Antral follicle counts assessed by ultrasound 72 
scan measure the same biological entity and show a strong positive correlation with serum 73 
AMH levels(4).  74 
Age remains one of the most important determinants of ovarian reserve and fertility (5), 75 
with a natural decline due to a decrease in the number of oocytes and a reduction in oocyte 76 
quality. Additionally, genetic, life-style  and environmental factors are also recognised to 77 
affect variation in ovarian reserve(5, 6). The relationship between smoking and serum AMH 78 
and AFC reported in literature is inconsistent. Some studies suggest that smoking may 79 
negatively impact the ovarian reserve(7, 8), whereas the others have failed to corroborate 80 
this association(9).Differences in ascertainment of cigarette smoking exposure, potential 81 
inaccuracies in self-reported smoking history and selection biases in studies may have led to 82 
discrepancies in the results. The role of passive smoking has also not been well investigated.  83 
Thus, the primary objective of our study was to assess the effect of cigarette smoking on the 84 
quantitative ovarian reserve parameters, AMH and AFC. Our secondary aims were to 85 
validate self-reported smoking behaviour using biomarkers and evaluate the association 86 
between biomarkers of ovarian reverse (serum AMH and AFC) with biomarkers of smoking 87 




































































2 Materials and methods 89 
2.1 Study design, setting and population 90 
We conducted a single-centre prospective cross-sectional study from July 2019 to February 91 
2020. The study population comprised of couples referred to the fertility centre for 92 
investigations and treatment of subfertility. We compared the levels of serum AMH and AFC 93 
among current smokers, ex-smokers and never-smokers based on a self-reported smoking 94 
history and validated by the measurements of breath carbon monoxide (CO) and urine 95 
cotinine levels. We also explored the association between biomarkers of ovarian reserve 96 
(AMH and AFC) and biomarkers of smoking (breath CO and urine cotinine) and correlated 97 
the lifetime smoking exposure quantified as “pack years” with levels of serum AMH and 98 
AFC.  99 
2.2 Inclusion and exclusion criteria 100 
We included women aged 35 years attending the fertility unit for investigations and 101 
treatment. We excluded women on long term oral contraceptive pills or GnRH analogues, 102 
those not having both ovaries and with a history of previous chemotherapy, 103 
abdominal/pelvic radiotherapy or major ovarian surgery. 104 
2.3 Study procedures, screening, consent, care pathway, study intervention, 105 
laboratory procedures 106 
We screened and invited eligible participants to participate in the study. Following informed 107 
consent we assessed the participants for markers of smoking. This included a short self-108 
reported questionnaire about the participant’s current and past smoking history, a non-109 
invasive breath test to detect the levels of carbon monoxide and a urine test to detect the 110 
levels of cotinine. Based on the smoking history we classified participants into one of three 111 
categories; current smokers, ex-smokers and never-smokers. The smoking history also 112 
accounted for passive smokers and smoking details aimed to quantify the smoking exposure 113 
in terms of “pack years”. We measured serum AMH and AFC as a part of the standard 114 
fertility work up done for all fertility patients. We also collected baseline demographic and 115 
clinical data for confounding variables. We followed up all participants for the results of 116 




































































2.4 Products, devices, techniques and tools 118 
A bespoke questionnaire was used to obtain self-reported smoking history. This was 119 
designed with the input of clinical and research members of the team to ensure content 120 
validity and reliability. The questionnaire was tested on a pilot sample of the target 121 
population. This highlighted deficiencies and allowed improvements in the final 122 
questionnaire used. The questionnaire details are provided in Appendix S1.  123 
The device used to measure the breath CO (Smokelyser) is a CE marked, commercially 124 
available, non-invasive CO breath test that uses an electrochemical sensor to measure the 125 
breath concentration of CO with a concentration range of 0-150 ppm with a sensor 126 
sensitivity of 1 ppm and an accuracy of 2 ppm. The instrument was used within the 127 
specified warranty period and used and serviced according to manufacturer’s specifications. 128 
The urine cotinine was measured using the DRI®Cotinine assay (Thermo Fisher Scientific). 129 
The DRI® Cotinine Assay is an in vitro diagnostic medical device intended for the qualitative 130 
and semi-quantitative determination of cotinine in human urine at a cut off level of 500 131 
ng/mL. The accuracy of the assay has been confirmed by gas chromatography /mass 132 
spectrometry. According to manufacturer, the sensitivity, defined as the lowest 133 
concentration that can be differentiated from the negative urine calibrator with 95% 134 
confidence, is 34 ng/mL. 135 
All serum AMH assays were performed in an on-site clinical laboratory using the bench-top 136 
fully automated assay Access 2 immunoassay system (Beckman-Coulter) and values were 137 
expressed as pmol/l. Inter-assay coefficients of variation for a low and high control were 138 
0.056 and 0.44, respectively. Venous blood samples were obtained and delivered to the 139 
laboratory immediately, centrifuged, and stored at 2-8°C, and analysed every day.  140 
Ultrasound imaging of ovaries was performed using a Voluson S10 diagnostic ultrasound 141 
system (GE Healthcare) equipped with a multi-frequency transvaginal probe (RIC5-9W-RS: 9-142 
5MHz) to visualize antral follicles systematically. AFC was obtained automatically using the 143 
sono-AVC™ software. Manual image post-processing was done if required. A total AFC was 144 
calculated as the sum of total number of follicles between 2-9 mm on each ovary. This 145 




































































2.5 Outcome measures 147 
The primary outcome measures were serum AMH and total AFC. 148 
2.6 Data collection 149 
Data were recorded onto study specific paper Case Report Forms (CRFs) and subsequently 150 
transferred to a study database. We collected baseline demographic characteristics of the 151 
study population (age, ethnicity), baseline clinical data (BMI, presence of PCO/PCOS, history 152 
of ovarian surgery), data for on smoking parameters (type of smoker, passive smoking, 153 
smoking in pack years, breath CO and urine  cotinine levels) and data for primary outcomes 154 
(serum AMH, AFC). 155 
Data for smoking parameters were collected by members of the research team directly from 156 
the participant. All other data were collected from the participants’ medical records and 157 
electronic hospital records.  158 
2.7 Statistical considerations, sample size, analysis 159 
The sample size calculation was based upon the primary outcome of serum AMH. 160 
Approximately 13% of women in the UK are current smokers (10) and the number of ex-161 
smokers exceeds that of smokers. The proportion of never smokers in the UK population is 162 
increasing and reported at 59% in 2014 (11). Hence we estimated that at the fertility clinic 163 
approximately one third of our population would be either smokers or ex-smokers. We have 164 
previously found the mean serum AMH to be 28.28 pmol/l and a significantly lower 165 
pregnancy rates among women in the lowest quartile of AMH, i.e. below 10.28 pmol/l.(12) 166 
To detect an absolute decrease in AMH from 28.28  to 10.28 pmol/l with 80% power at a 5% 167 
significance level with an enrolment ratio of 0.5, we would require 96 participants (32 168 
smokers/ex-smokers and 64 non-smokers). We planned to recruit approximately 100 169 
participants to compensate for dropout and loss to follow up. Appropriate descriptive 170 
statistics were used to describe the baseline variables in the dataset. Normality of data was 171 
checked using Shapiro-Wilk test and skewed data were log transformed to achieve normal 172 
distribution before using parametric test. Nonparametric tests were used for data analysis if 173 
normal distribution was not achieved.  An one-way between-groups analysis of variance 174 
(ANOVA), a Chi-squared test or a Kruskal-Wallis test were used to assess differences 175 




































































and never smokers. An ANOVA was used to assess differences in outcome variables 177 
between the three study groups. When the P-value was <.05, the difference was considered 178 
statistically significant. When a difference was found to be significant, a post-hoc Tukey 179 
multiple comparison test was performed. A one-way between-groups analysis of co-180 
variance (ANCOVA) was performed to assess the differences between groups taking into 181 
account the variability of other confounding variables. Differences in breath CO 182 
concentrations and urine cotinine levels in the three comparison groups were used to 183 
validate group stratification and the results for the primary outcome variables. Pearsons 184 
correlation test was used to explore the relationship between lifetime exposure to smoking 185 
(pack years), breath CO or urine cotinine and outcome variables. Statistical analysis was 186 
done using the Statistical Package for Social Sciences (SPSS version 26). 187 
3 Results 188 
101 women were recruited to the study over a period of  nine months. Based on a self-189 
reported smoking history women were classified into three comparison groups: current 190 
smokers, ex-smokers and never smokers. The baseline clinical characteristics of the 191 
participants are summarised in Table 1. There were no significant differences in the baseline 192 
variables amongst the three groups. 193 
The smoking markers for the three groups are detailed in table 2. The pack years of 194 
smoking, quantifying exposure to cigarette smoking, were not significantly different 195 
between current and ex-smokers (F(1,25) = 0.547, p=0.467). The breath CO levels were 196 
significantly different amongst current, ex- and never smokers (F(2,97) = 33.32, p< 0.0001). 197 
Urine cotinine levels were also significantly higher in current smokers as compared to ex-198 
smokers and never smokers. (p< 0.001). Current smokers reported to be more exposed to 199 
passive smoking (75%, 9/12) as compared to ex-smokers (20%, 5/25) and never smokers 200 
(25%, 16/64) (p=0.001). 201 
No significant difference was observed amongst current, ex- and never smokers either for 202 
serum AMH (F(2,91) = 1.19, p=0.309) or total AFC (F(2,81) = 0.403, p= 0.670). When 203 
comparing baseline variables, age showed borderline non-significance between the groups 204 




































































of smoking status on serum AMH using age as a covariate. No significant difference was 206 
demonstrated among the three groups (F(2,90) = 0.398, p = 0.673). 207 
No significant correlation was demonstrated between the pack years of smoking and serum 208 
AMH (r= -0.212, n=23, p=0.166) or total AFC (r= -0.276, n=19, p=0.126). No significant 209 
correlation was found between breath CO and serum AMH (r= 0.082, n=94, p=0.216) or 210 
total AFC (r= 0.096, n=83, p=0.195). Similarly, no significant correlation was found between 211 
urine cotinine levels and serum AMH (r= 0.146, n=83, p=0.095) or total AFC (r= -0.027, n=77, 212 
p=0.386).  213 
4 Discussion 214 
4.1 Main results 215 
We did not find a statistically significant difference in quantitative ovarian reserve markers 216 
serum AMH and AFC between current, ex and never smokers in our study population. By 217 
demonstrating significant differences in breath CO and urine cotinine levels among the 218 
groups, we confirmed that self-reported smoking correlates well with quantitatively  219 
measured markers of smoking. We were hence able to validate the comparison groups 220 
created by a self-reported history to ensure a valid comparison of outcome measures. We 221 
were unable to demonstrate a significant correlation between the pack years smoked and 222 
serum AMH and AFC. We did not find a significant association between biomarkers of 223 
smoking and biomarkers of ovarian reserve. 224 
4.2 Interpretation of results 225 
Biological plausibility exists for the effect of smoking on ovarian reserve and ovarian ageing.  226 
Animal studies have suggested adverse effects of cigarette smoking on ovarian 227 
reserve (13, 14). Several mechanisms have been postulated, which may affect quality, 228 
quantity or both. Gannon et al in 2012 (15) hypothesised a mechanism of direct toxicity to 229 
ovarian follicles resulting in an accelerated follicle loss. An indirect effect on ovarian follicle 230 
numbers has been suggested through an action on the hypothalamic pituitary axis (16) . 231 
These effects are however not evident in our study population of younger women based on 232 




































































This may be because the natural decline of ovarian reserve with age does not follow a linear 234 
function but shows a rapid decline with increasing age(5).It has also been suggested that 235 
ovarian follicles may differ in susceptibility to the effects of smoking at different ages with 236 
older oocytes being more susceptible to negative effects of smoking. 237 
The effect of smoking may be dose related. The pack years of smoking in our study 238 
population was relatively low at 2.13 pack years. It is possible that the deleterious effects 239 
are evident only at higher levels of smoking exposure or smoking is associated with smaller 240 
magnitude of reduction in ovarian reserve markers. Although it may be possible to 241 
demonstrate such small differences with a larger sample size, the clinical implications of 242 
such findings would be questionable. Serum AMH and AFC are largely used in young women 243 
in the context of fertility treatment, to predict ovarian response to treatment and 244 
pregnancy rates. Hence in younger women seeking fertility treatment , a clinically relevant 245 
decrease in ovarian reserve may be considered one which significantly reduces the 246 
probability of the most important outcome for this group of women; the pregnancy rate. 247 
Significantly lower pregnancy rates have been reported in the lowest quartile of AMH below 248 
10.28 pmol/l(12).  Pregnancy rates in women with serum AMH in the upper three quartiles 249 
are not statistically different from each other.(12).  The absence of an association between 250 
smoking and serum AMH and AFC also argues for a mechanism against follicular atresia. This 251 
is strengthened by the finding of no association between ex-smokers and lower AMH values 252 
in our study and also in other studies such as Dolleman et al(7).  253 
Our results are in agreement with those of Bressler et al, 2016 (9). They were unable to 254 
demonstrate an association between smoking exposure and serum AMH in a population 255 
based cross-sectional analysis. The age of their study population was women aged 23-35 256 
years which is similar to that of our study. However, exposure ascertainment was done 257 
using only a self-reported questionnaire. Similarly, Kline et al in 2016 reported no 258 
association between AMH and smoking in a cross-sectional study using self-reported 259 
smoking to ascertain exposure. Dolleman et al in 2013 in a large population based study 260 
reported lower serum AMH in current smokers but not in ex-smokers as compared to never 261 
smokers. The study population was however significantly older (mean 37.3, SD 9.2) than our 262 
study population, which may explain a difference in the results. It has been suggested that 263 




































































age(16). Also, the smoking exposure in pack years was higher in this population (mean 10.2, 265 
SD 9.1) as compared to our study (median 2.13 (IQR 0.59-3.48)) which could account for the 266 
differences. Dolleman also reported a threshold after which the linear association of pack 267 
years and serum AMH was significant. They reported this at 10 pack years of smoking below 268 
which there was no significant association with serum AMH. Hence, these results could be 269 
considered to be in agreement with our study. 270 
We have used breath CO and urine cotinine as biomarkers of smoking to validate self -271 
reported smoking history. This is in agreement with previously reported studies. Marrone et 272 
al report significantly higher breath CO and cotinine levels in smokers compared with non-273 
smokers (P<0.001), with 100% specificity and sensitivity at a concentration of 5ppm(17). 274 
Similarly, MacLaren et al reported a strong agreement between self-reported smoking and 275 
breath CO levels with a sensitivity of  96% and specificity of 93.3% using a cut off of 276 
7ppm(18).  277 
4.3 Strengths and limitations 278 
A major strength of our study is that we used a comprehensive and detailed self-reported 279 
questionnaire to assess smoking exposure, which allowed estimation of lifetime smoking 280 
exposure in terms of pack years and also accounted for passive smoking. Furthermore, we 281 
also used breath CO and urine cotinine concentrations to validate our study groups. The CO 282 
breath test shows the amount of CO in the breath (ppm), as an indirect, non-invasive 283 
measure of blood carboxyhemoglobin (%COHb). CO leaves the body rapidly and the half-life 284 
is about 5 hours. Within 24 to 48 hours of not smoking, smokers will be at non-smoker 285 
levels. Cotinine is the predominant metabolite of nicotine. It has a half-life of 20 hours and is 286 
detectable for up to one week after the use of tobacco. This is useful to identify smokers 287 
who have abstained from smoking for several hours.  288 
The participants included an unselected population of women attending the clinic for 289 
various investigations and treatments. There were wide variations in the baseline 290 
characteristics of participants such as ethnicity, cause of infertility and diagnosis. By using a 291 
wide-ranging unselected population of women we have attempted to improve the 292 




































































Age remains a major determinant of ovarian reserve. We have included only women 35 294 
years and younger to reduce bias due to the impact of advancing age. The participants 295 
included only sub-fertile women with a limited range of BMI and age. This is because fertility 296 
treatment within the UK and funded by the National Health Service is restricted by limits on 297 
age and BMI. Therefore,  caution should be exercised when extrapolating these results to 298 
other populations. Our study was powered only to detect differences in ovarian markers of 299 
relatively large magnitude that we considered to have a clinical significance in the 300 
management of young women seeking fertility treatment   However, a much larger sample 301 
size would be required to detect statistically significant differences of smaller magnitude 302 
which may be relevant to different study populations and research questions.  303 
5 Conclusion 304 
We did not find a quantitative change in the antral follicle pool following exposure to 305 
cigarette smoking in women 35 years  seeking fertility treatment. We confirmed that self-306 
reported smoking correlates well with quantitatively  measured biomarkers of smoking. 307 
There was no significant association between biomarkers of smoking and biomarkers of 308 
ovarian reserve. We were also unable to demonstrate a correlation between the lifetime 309 
smoking exposure and ovarian reserve parameters 310 
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Table 1: Baseline variables 
 







Age (years) 30 (25.5-33.0) 32.5 (31.0-33.5) 31.0 (28.0-33.0) 0.057
 
BMI 23.2 (21.8-26.2) 25.3 (20.8-28.3) 25.1 (22.1-27.8) 0.632 
Ethnicity    0.208 
White European  8 21 35  
Asian 2 4 16 
Afro-Caribbean 1 0 8 
Others 1 0 5 
Category of infertility    0.077 
Anovulatory 4 1 11  
Male 4 5 14 
Tubal 2 0 9 
Unexplained 1 14 20 
Other 0 4 4 
Ovarian surgery    0.659 
No 12 23 60  
Yes 0 1 1 
PCOS/PCOM    0.351 
N 7 17 42  
Y 5 4 20 
Values expressed as median (IQR) or n 
Table 1
Table 2: Smoking markers 
 







Pack years of 
smoking 
2.13 (0.59-3.48) 2.13 (0.05-5.40) 0.00 (0.00-0.00) 0.467* 
Breath CO 
(ppm) 
9 (3.5-21) 2 (2-3) 1 (1-2) <0.001 
Urine Cotinine 
(ng/ml) 







*comparison between current and ex-smokers only 
Values presented as median (IQR) 
Table 2
Table 3: Outcomes 
 
 Current smokers 
(n=12) 





38.9 (20.4-66.2) 26.0 (14.7-32.2) 27.6 (16.4-39.7) 0.309 
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mone,	antral	 follicle	count	and	 reproductive	outcomes	 in	women	with	polycystic	
ovary	syndrome	undergoing	IVF/ICSI.
Material and methods: We	performed	a	literature	search	using	standard	methodology	
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1  | INTRODUC TION
Ovarian	 reserve	markers,	 anti‐Mullerian	hormone	 (AMH)	and	antral	











glucose	uptake	by	oocytes	 secondary	 to	 insulin	 resistance	 is	postu‐
lated	to	result	in	poor	quality	oocytes	and	subsequently	embryos.5


















In	view	of	 their	hypothesized	benefits,	 inositols	 are	commonly	




ICSI	 treatment.	Although	 inositols	have	been	 reported	 to	 improve	
menstrual	 regularity	 and	 ovulation	 rates,13	most	 studies	 assessing	
the	 effects	 of	 inositol	 on	 ovarian	 function	markers/IVF	 outcomes	






selection	criteria	 it	presents	only	 two	randomized	controlled	 trials	
and	none	of	the	outcomes	presented	in	this	review.
Thus	our	primary	objective	was	to	assess	the	effect	of	 treatment	
with	myo‐inositol	 (MI)/di‐chiro	 inositol	 (DCI)	 compared	with	no	 treat‐




2  | MATERIAL AND METHODS
2.1 | Eligibility criteria
All	 published	 studies,	 randomized	 controlled	 trials	 (including	 cross‐
over	trials)	supplemented	by	non‐randomized	studies	such	as	quasi‐












Conclusions: There	 is	 insufficient	evidence	for	an	effect	of	 inositols	on	ovarian	re‐
serve	markers	and	to	support	their	use	as	pretreatment	before	 IVF/ICSI	 in	women	
with	polycystic	ovary	syndrome.
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(metaphase	 II)	 oocytes,	 number	 of	 top‐grade	 embryos,	 pregnancy	
rate,	live	birth	rate	and	risk	of	OHSS.
2.4 | Data sources
The	authors	P.B.	 and	 J.P.	 independently	 screened	and	 identified	 rel‐
evant	studies	for	the	review.	We	used	both	electronic	searches	of	bib‐
liographic	databases	and	hand‐searching	as	described	in	the	Cochrane	
Handbook	 for	 Systematic	 Reviews	 of	 Interventions.	 An	 up‐to‐date	
search	 for	any	 recent	data	was	conducted	1	month	prior	 to	submis‐
sion	of	this	systematic	review.	We	searched	the	electronic	databases	
MEDLINE,	 Embase,	 CENTRAL	 and	 CINAHL.	 The	 study	 period	 was	
from	 inception	 till	 31	December	2017.	The	 search	 strategy	 included	




in	 Supporting	 Information	Appendix	S1.	A	 similar	 strategy	was	used	
for	the	other	databases	searched.	We	also	searched	other	published	
reviews	and	guidelines.	The	reference	 lists	of	all	known	primary	and	










the	 review.	 In	 the	case	of	disagreement,	 a	 third	author	 (G.A.)	was	
consulted	and	consensus	reached	for	inclusion/exclusion	of	the	ar‐
ticle	in	question.











mean	 difference	 (SMD)	 for	 continuous	 variables	 with	 95%	 confi‐
dence	intervals	using	the	random	effects	model	and	inverse	variance	
method.	Statistical	 significance	was	assumed	when	P	 <	 .05.	When	
published	articles	were	unclear	about	the	presence	and	amount	of	
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3  | RESULTS
3.1 | General characteristics of the studies





Seven	 studies	 assessed	 changes	 in	 ovarian	 reserve	 markers.	 Twelve	


















the	 included	 studies21,23,24,28,29	 assessed	MI	 in	 varying	doses	 ranging	
from	1	to	4	g	daily	and	for	varying	durations	between	12	weeks	and	
6	months	with	no	explanations	for	variations	in	dose	or	duration	of	given	





3.2.2 | Studies assessing reproductive outcomes 
after IVF/ICSI





based	 on	 age,	 body	 mass	 index	 and	 insulin	 resistance,	 the	 details	
of	 which	 are	 included	 in	 Table	 S2.	 Nine	 of	 the	 12	 included	 stud‐





F I G U R E  1  Risk	of	bias	in	included	studies.	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
Risk of bias for non-randomised studies (ROBINS-I tool):
Risk of bias summary for randomised studies (Cochrane RoB tool):































Quasi randomised Moderate risk Moderate risk Low risk No information Low risk Low risk Moderate risk Moderate risk 
2 Alviggi, 201628 Retrospective 
controlled before 
and after study 
Moderate risk No information Moderate risk No information Low risk Low risk Moderate risk Moderate risk 
3 De Cicco, 
201729 
Before and after 
study 
Serious risk No information Low risk Low risk Low risk Low risk Moderate risk Serious risk 
4 Ozay, 201721 Quasi randomised Moderate risk Moderate risk Low risk Serious risk Serious risk Low risk Moderate risk Serious risk 
5 La Marca, 
201530 
Retrospective 
before and after 
study 





No information Moderate risk Low risk No information No information Low risk Moderate risk Moderate risk 
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3.2.4 | Synthesis of the results
Primary outcomes
Anti-Mullerian Hormone. Due	 to	 clinical	 and	 methodological	
heterogeneity,	 none	 of	 the	 studies	 using	 MI/DCI	 were	 suitable	
for	 inclusion	in	a	meta‐analysis	for	this	outcome.	The	SMDs	in	the	
levels	 of	 serum	 AMH	 before	 and	 after	 treatment	 with	 inositols	
for	 the	 five	 individual	 studies	 with	 172	 participants	 are	 shown	
in	 Figure	 2.	 There	 was	 no	 consistent	 direction	 or	 size	 of	 effect.
Antral follicle count. Due	 to	 clinical	 and	 methodological	
heterogeneity,	none	of	the	four	studies	using	MI/DCI	was	suitable	
for	 inclusion	 in	a	meta‐analysis.	The	SMDs	 in	 the	AFC	before	and	
after	 treatment	 for	 the	 individual	 studies	 with	 143	 participants	
are	 shown	 in	 Figure	 2.	 The	 results	 show	 a	 high	 heterogeneity	
in	 effect	 size	 for	 AFC.	 The	 results	 do	 not	 suggest	 any	 clear	
change	 in	 AMH	 or	 AFC	 values	 following	 treatment	 with	 inositol.
Secondary outcomes
Number of retrieved oocytes. Of	 the	11	studies	 reporting	 the	number	
of	oocytes	retrieved,	7	RCTs	with	722	participants	were	 included	 in	
the	 meta‐analysis.	 No	 statistically	 significant	 difference	 was	 found	
between	the	intervention	and	control	arms	(MD	−.39,	95%	confidence	









difference	 between	 the	 MI	 and	 control	 groups	 (P	 =	 .23).	 Unfer12 
compared	treatment	with	MI	with	treatment	with	DCI	and	reported	
no	 significant	difference	between	 the	number	of	 retrieved	oocytes.
Number of metaphase II oocytes. Of	the	10	studies	reporting	on	the	
number	of	metaphase	 II	 oocytes	 retrieved,	 only	3	RCTs	with	207	
participants	 were	 included	 in	 the	 meta‐analysis.	 No	 statistically	
significant	 difference	 was	 observed	 between	 the	 intervention	
F I G U R E  2  Forest	plot	of	comparison:	Ovarian	reserve	markers	before	and	after	treatment	with	inositol
Analysis 1: Forest plot of comparison: Ovarian reserve markers before and after treatment with inositol, Antimullerian hormone.
Analysis 2: Forest plot of comparison: Ovarian reserve markers before and after treatment with inositol, Antral follicle count.
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F I G U R E  3  Forest	plot	of	comparison:	Inositol	vs	control,	reproductive	outcomes	for	IVF/ICSI.	(A)	Number	of	retrieved	oocytes;	(B)	
number	of	MII	oocytes;	(C)	number	of	top‐grade	embryos.	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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and	control	arms	 (MD	.29,	95%	CI	−.83	to	1.40).	The	results	were	
similar	 for	 a	 subgroup	 analysis	 for	MI	 (MD	−.32,	 95%	CI	 −1.49	 to	
.86).	 A	 single	 trial,	 Piomboni	 et	 al33	 reported	 significantly	 higher	
number	 of	 MII	 oocytes,	 with	 a	 moderate	 effect	 size,	 following	
treatment	 with	 DCI	 as	 compared	 with	 control	 (MD	 1.30,	 95%	
CI	 .15‐2.45).	 The	 results	 are	 shown	 in	 Figure	 3.	 Data	 from	 other	
studies	were	 not	 available	 in	 a	 format	 suitable	 for	meta‐analysis.	




a	 significant	 decrease	 in	 the	 number	 of	 MII	 oocytes	 following	
treatment	 with	 DCI	 as	 compared	 with	 control.	 The	 results	 from	
Lesoine	&	Regidor20	are	unclear.	Alviggi	et	al28	in	a	non‐randomized	
study	reported	a	significant	increase	in	the	number	of	MII	oocytes	
following	 treatment	 with	MI	 as	 compared	 with	 control	 (P	 =	 .03).	
Unfer	et	al12	compared	treatment	with	MI	with	treatment	with	DCI	
and	 reported	 a	 significant	 increase	 in	 the	 number	 of	MII	 oocytes	
following	 treatment	 with	 MI	 as	 compared	 with	 DCI	 (P	 <	 .05).
Number of top-grade embryos. Four	of	the	eight	RCTs	including	957	
participants	and	reporting	the	number	of	top‐grade	embryos	were	
included	 in	 the	meta‐analysis.	 No	 significant	 difference	 was	 seen	
between	 the	 groups	 (RR	 1.02,	 95%	 CI	 .93‐1.12).	 The	 other	 four	
studies	 reporting	 this	 outcome	 did	 not	 contain	 data	 in	 a	 suitable	
format	 and	 hence	 could	 not	 be	 included	 in	 the	 meta‐analysis.	
The	 results	 are	 shown	 in	 Figure	 3.	 Pacchiarotti	 et	 al22	 reported	
no	 significant	 difference	 in	 the	 number	 of	 top	 grade	 embryos	
between	 the	 MI	 and	 control	 groups.	 Isabella	 et	 al19	 reported	 a	
significant	decrease	in	the	number	of	top‐grade	embryos	following	
treatment	with	DCI	(P	<	.01)	whereas	Lesoine	&	Regidor20	reported	
a	 significantly	 higher	 number	 of	 top‐grade	 embryos	 following	
treatment	 with	 MI	 as	 compared	 with	 control	 (P	 <	 .05).	 Unfer	 et	
al12	 reported	 a	 significantly	 higher	 number	 of	 top‐grade	 embryos	
following	 treatment	 with	 MI	 than	 treatment	 with	 DCI	 (P	 <	 .01).
Clinical pregnancy rate. Three	 RCTs	 with	 488	 participants	
reporting	 clinical	 pregnancy	 rates	 were	 included	 in	 the	 meta‐
analysis.	 No	 significant	 difference	 was	 seen	 between	 the	
groups	 (RR	 1.16,	 95%	 CI	 .87‐1.53).	 The	 results	 are	 shown	 in	
Figure	 4.	 Schillaci	 et	 al,34	 Alviggi	 et	 al28	 and	 Wdowiak	 et	 al25 
did	 not	 indicate	 whether	 the	 pregnancies	 were	 biochemical	 or	
clinical.	 No	 significant	 differences	 were	 reported	 between	 the	
groups	 in	 these	 studies.	 Unfer	 &	 Regidor12	 compared	 treatment	
with	 MI	 with	 treatment	 with	 DCI	 and	 reported	 no	 significant	
difference	 in	 clinical	 pregnancy	 rates	 between	 the	 groups.
Live birth rate. Only	 one	 trial,	 Artini	 et	 al,32	 reported	 live	 birth	
rate.	 This	 reported	 a	 significant	 improvement	 in	 live	 birth	 rate	
following	 treatment	 with	 MI	 compared	 with	 placebo	 (P	 <	 .05).
Risk of cycle cancellation due to the risk of OHSS. Six	 of	 the	 seven	
studies	 reporting	 cycle	 cancellations	 due	 to	 the	 risk	 of	 OHSS	
were	 included	 in	 the	meta‐analysis.	 No	 significant	 difference	was	
seen	between	 groups	 (RR	 .73,	 95%	CI	 .39‐1.37).	 The	 results	were	
similar	for	a	subgroup	analysis	for	MI	(RR	.70,	95%	CI	.34‐1.42)	and	
DCI	 (RR	 .85,	95%	CI	 .22‐3.29).	 The	 results	 are	 shown	 in	Figure	4.
4  | DISCUSSION










was	 no	 significant	 difference	 between	 the	 rates	 of	 cycle	 cancel‐









ICSI	 treatment.5,14,15,26	The	 first	 systematic	 review	by	Unfer	et	al5 
reported	an	 improvement	 in	oocyte	 and	embryo	quality	based	on	
five	studies.	The	findings	of	that	review	disagree	with	those	of	our	
review.	The	conclusions	of	 that	 review	were,	however,	based	on	a	
narrative	 systematic	 review	 rather	 than	 a	meta‐analysis.	 It	 is	 pos‐

















IVF/ICSI	 treatment	 and	provide	a	pooled	effect	 estimate.	Women	
with	PCOS	are	at	an	inherently	greater	risk	of	OHSS	following	IVF/
ICSI	 treatment	 and	 this	 remains	 an	 important	 safety	 outcome	 for	
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any	 trial	 intervention.	Although	Mendoza	et	al	have	discussed	 the	
limitations	 of	 the	 included	 literature	 in	 terms	of	 study	 design	 and	
methodology,	we	have	provided	a	formal	and	hence	more	objective	
assessment	of	the	quality	of	evidence	included	and	certainty	of	the	






F I G U R E  4  Forest	plot	of	comparison:	Inositol	vs	control,	reproductive	outcomes	for	IVF/ICSI.	(A)	Clinical	pregnancy	rate;	(B)	cycle	
cancelation	due	to	the	risk	of	ovarian	hyperstimulation.	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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on	only	two	outcomes	investigated	by	this	review	(live	birth	and	clin‐

















Where	 information	 was	 missing,	 we	 attempted	 to	 contact	 the	
study	authors	on	multiple	occasions	to	seek	as	much	information	
for	inclusion	as	possible.	We	have	received	information	from	some	
authors	but	were	unable	 to	get	 information	 from	several	others.	
We	 were	 hence	 unable	 to	 include	 data	 from	 these	 studies	 and	










androgens.	This	can	be	used	 to	modify	 treatment	protocols	 to	 re‐
duce	the	risks.
Inositols	are	available	as	over‐the‐counter	nutritional	supplements	

















In	 conclusion,	 the	 findings	 from	 this	 systematic	 review	 do	 not	
provide	adequate	evidence	for	changes	to	the	antral	 follicle	pool	
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Abstract
Purpose Serum anti-Mullerian hormone shows a strong
positive correlation to the quantitative ovarian reserve but
its correlation to embryo quality is unclear. This study
assessed the association between serum AMH as a marker
of ovarian reserve and embryo quality, using the technol-
ogy of time-lapse imaging of the embryos in women
undergoing in vitro fertilisation (IVF) treatment.
Methods 304 embryos from 198 women undergoing IVF
were included in the study. Serum AMH was assessed for
all women. Embryo quality was assessed with the known
implantation data (KID) score generated by the time-lapse
imaging system.
Results There was no statistically significant difference in
mean serum AMH among different KID score categories
(p = 0.135). This remained non-significant after control-
ling for confounding variables (p = 0.305).
Conclusions The results of our study show no significant
association between serum AMH and embryo quality in
women undergoing IVF treatment when embryo quality
was assessed using the KID scores generated by time-
lapse imaging which is a better method of embryo
assessment rather than conventional morphological
assessment.
Keywords Anti-Mullerian hormone  Embryoscope 
Time-lapse imaging  Ovarian reserve
Introduction
Anti-Mullerian hormone (AMH) produced by the granu-
losa cells of the ovary is an indicator of ovarian reserve.
It is an excellent predictor of response to controlled
ovarian stimulation in in vitro fertilisation (IVF)/intra-
cytoplasmic sperm injection (ICSI) treatment [1].
Although a strong positive correlation between serum
AMH levels and number of oocytes retrieved during IVF
is reported [2–4], previous studies have not shown a clear
correlation between AMH and embryo quality [5–7].
Embryo quality in these studies is evaluated using stan-
dard morphological assessment of developing embryos
[5–7]. The predictive ability of standard morphological
assessment for successful pregnancy remains poor [8] and
methods for improved embryo selection are constantly
being sought. Time-lapse imaging systems provide more
detailed, objective and reproducible assessment of embryo
development and quality compared to standard morpho-
logical assessment [9].
This study aimed to assess the association between
ovarian reserve and embryo quality using the newer tech-
nology of time-lapse imaging. This was done by examining
the correlation between serum AMH levels as a marker of
ovarian reserve and ‘KID’ (Known Implantation Data)
scores generated by time-lapse imaging of the developing
embryos as an indicator of embryo quality.
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Materials and methods
A single centre, cross-sectional observational study was
conducted at a university IVF clinic in the UK from June
2014 to December 2016. Eligible participants included
couples having IVF/ICSI treatment during the recruitment
period with embryos cultured and assessed in time-lapse
incubators and with known implantation data. Thus, the
study included all women with a single embryo transfer
and those women with two embryos transferred who either
had a negative pregnancy test or a dichorionic twin preg-
nancy. The participants were followed from the start of
their IVF/ICSI treatment up to a time when either a clinical
pregnancy or a negative pregnancy test was established.
Data were collected from medical notes and electronic
patient records. Collected data included serum AMH level
and the KID score generated by the time-lapse system.
Serum AMH is measured as a part of the routine baseline
investigations for all women attending the fertility clinic
and proceeding to IVF/ICSI treatment. Measurement of
AMH was not restricted to a particular time of the men-
strual cycle. All AMH assays were performed using the
Beckman Coulter Generation II assay, and values were
expressed as pmol/l. Inter-assay coefficients of variation
for a low and high control were 10.3 and 10.0%, respec-
tively. The time-lapse system used was the Embryoscope
(Vitrolife, Sweden). Embryos were placed in the time-lapse
incubators following IVF fertilisation check/ICSI and
assessed on day 3 of embryo culture. Each embryo was
annotated for five variables related to timing and syn-
chronicity of cell divisions (morphokinetic parameters)
which were combined to generate a composite score—KID
score. The variable annotations are, time of pronuclear
fading-tPNf, time of first cell division to two cells—t2,
time of 3 cells—t3, time of 4 cells—t4 and time of 5
cells—t5. The models are based on deselection of embryos
showing erratic morphokinetic patterns rather than selec-
tion intervals. The range of available scores was 1–5 with
five denoting the best embryo quality and one a poor
embryo quality. One or two embryos were replaced either
on day 3 or day 5 of culture depending on the number and
quality of available embryos. A pregnancy test, serum beta
HCG, was done 14 days after embryo transfer. The primary
outcome was the correlation between serum AMH and KID
score. Secondary outcome measures were pregnancy rate
(positive beta HCG) and clinical pregnancy rate. A positive
pregnancy test was defined as levels of serum beta HCG
greater than 30 IU/ml. Clinical pregnancy was defined as
the presence of at least one fetal heartbeat seen on ultra-
sound scan. Data was also collected for confounding
variables such as age, BMI, smoking status (current
smokers and self-reported) and method of insemination
(IVF/ICSI).
Statistical methods
Statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS Version 20). Basic
descriptive statistics were used to describe all the variables
in the dataset. The Kolmogorov–Smirnov test of normality
was performed to assess distribution of the data. Skewed
data was transformed prior to analysis using log transfor-
mation. A one-way between group’s analysis of variance
(ANOVA) or a Chi-squared test was performed depending
on the type of data for all univariate analysis. When
p\ 0.05, the difference was considered to be statistically
significant in all tests. When a difference was found to be
significant, a post hoc Tukey’s multiple comparison test
was performed. Analysis of covariance (ANCOVA) was
used to test for differences of AMH levels between KID
scores while controlling for confounding factors. To
explore the relative impact of serum AMH and the number
of retrieved oocytes on the pregnancy rate, we performed a
logistic regression analysis with pregnancy as a binary
outcome variable and serum AMH and number of oocytes
as explanatory variables.
Local Institutional Review Board approval was obtained
(Ref No. 1675) and all data collection was done in accor-
dance with data protection rules.
Results
A total of 198 women and 304 embryos were included in
the study, as some women had more than one embryo
transferred to the uterine cavity. The baseline characteris-
tics of the participants are summarised in Table 1.
Participants were grouped into five categories based on
their KID score. A univariate analysis (ANOVA) for each
of the variables was done for the different KID score cat-
egories. The results are summarised in Table 2.
Table 1 Baseline characteristics of the study polulation
Age (years) 36 (33–39)
Body mass index 24 (22–27)
Current smokers 22 (7.2)
IVF/ICSI 88/216 (29/71)
Serum AMH (pmol/l) 12.95 (8.57–18.33)
KID scores 4 (2–5)
Oocytes retrieved 10 (6–13)
Values expressed as median (IQR) or number (%)
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There was no statistically significant difference in mean
serum AMH among different KID score categories as
determined by one-way ANOVA (F(4, 293) = 1.769,
p = 0.135).
An ANCOVA to test for differences in AMH levels
among KID scores while controlling for confounding
variables, such as age and method of insemination (IVF/
ICSI), showed no significant differences (p = 0.305).
Pregnancy rates were significantly different among differ-
ent KID score categories (p\ 0.001) but there was no
significant impact of serum AMH on the chance of preg-
nancy as shown in Table 3.
Discussion
Main results
The results of our study show no significant differences in
mean serum AMH levels among different KID score cat-
egories (1–5) generated by the time-lapse imaging system.
This indicates that serum AMH is not significantly asso-
ciated with embryo quality as determined by time-lapse
imaging. Our findings are in agreement with previous
studies assessing the relationship between AMH and
embryo quality assessed using other methods. Smeenk
et al. [7], in an observational study, correlated basal serum
AMH with embryo quality in 112 women undergoing
controlled ovarian stimulation and IVF/ICSI. Serum AMH
failed to show a predictive capacity with respect to embryo
quality. Fong et al. [5] reported on correlation between
basal serum AMH and embryo quality in 125 women
undergoing IVF. Women were randomly assigned to either
mild stimulation or conventional stimulation and parame-
ters were assessed in both groups. Although a positive
correlation was seen between serum AMH and embryo
quality in the mild stimulation group, no significant cor-
relation was seen in the conventional stimulation group.
The latter group of women is a similar population to our
dataset, and hence the results may be considered to be in
agreement. Results from the study by Silberstein et al. [6]
are not in agreement with our findings. This study com-
pares serum AMH levels measured on the day of hCG
trigger with embryo quality. Therefore, the discrepancy
could be attributed to a different time frame used for the
measurement of AMH. None of the previous studies
employed the KID scores for a qualitative assessment of
embryo quality.
Strengths and limitations
Embryo quality in previous studies was mostly evaluated
using standard morphological assessment. This involves a
single snapshot assessment of embryos at pre-specified
times following IVF. The number of cells, degree of
fragmentation and uniformity of the blastomeres are
incorporated into this embryo scoring system. Standard
morphological assessment has shown poor predictive
ability for optimal embryo selection and subsequent cor-
relation to pregnancy rates [8]. The time-lapse systems and
KID scores used in our study provide an objective and
reproducible assessment of embryo quality. The KID
Table 2 Baseline and outcome variables in KID score categories
No. KID 5 KID 4 KID 3 KID 2 KID 1 p
1 Serum AMH (pmol/l) 16.36 15.05 15.38 16.77 12.76 0.135
2 Age (years) 35.07 35.16 37.31 36.14 36.81 0.049*
3 Body mass index 24.73 24.66 25.72 23.91 23.34 0.411
4 Current smokers (as a % of smokers) 31.8% 40.9% 4.5% 4.5% 18.2% 0.660
5 Method of insemination: IVF/ICSI(%) 20.3/79.7 38.4/61.6 15.5/84.6 39.3/60.7 36.5/63.5 0.033*
6 Pregnancy rate (positive serum beta HCG, IU/L)(%) 37 15.1 0 21.7 11.5 \0.001*
Table 3 Results of logistic
regression analysis
95% CI for odds ratio Sig.
B (SE) Lower Odds ratio Upper
Constant -3.098 (0.749) 0.000
Serum AMH* 0.651 (0.570) 0.627 1.918 5.865 0.253
Number of oocytes* 1.243 (0.730) 0.829 3.468 14.501 0.088
* Data log transformed to fit normal distribution
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scores are generated by the manufacturers algorithm using
‘morphokinetic’ parameters. These parameters are gener-
ated based on the timing and synchronicity of early mitotic
divisions and abnormal cleavage patterns of embryos. KID
scores in our study show a strong correlation to pregnancy
rate, which is in agreement with previous studies [10].
These scores may be considered a more robust indicator of
embryo development and quality than previously used
standard assessment, and hence strengthen the validity of
our results as compared to previous studies. Embryo
quality is a reflection of both oocyte and sperm quality.
Oocyte and subsequently embryo quality is further
dependent on a number of variables such as age and life-
style factors such as smoking. Our study controls for these
confounding variables when assessing the relationship
between ovarian reserve and embryo quality.
The possibility of some selection bias cannot be exclu-
ded due to the observational design of the study. However,
we feel that this would not impact on the results, as the
study variables are objective and a wide range of serum
AMH and KID score values are present in the dataset.
There has been some recent concern about measurement
and reported values of serum AMH. This is related to the
instability of AMH and mainly caused by delays in pro-
cessing and long storage times for samples. As the samples
were delivered, spun, and stored at -20 C, and analysed
within 14 days in an onsite laboratory, we remain confident
about the accuracy of our measurements. The study was
conducted in the UK in a NHS funded IVF unit which
places age restrictions on the women being treated. We
hence have data only between 23 and 42 years of age and
the results only applicable to this age group. It is, however,
uncommon to have many women outside these age ranges
seeking fertility treatment. We recruited 198 women but
analysed the data for 304 embryos as some women had two
embryos replaced. Hence, some AMH values have been
duplicated in the analysis. Including only those women
with a single embryo transfer would have considerably
reduced the number of women in the dataset as only
25–30% of all transfers are single embryo transfers. The
smoking status of women in the study is self-reported and
we did not have confirmatory cotinine testing for partici-
pants. NHS funding for IVF/ICSI treatment is not available
for smokers, and this may have led to a reduced self-re-
porting of the condition. This is, however, unlikely to
affect the final outcomes as these women would be equally
distributed across the dataset.
Interpretation
Pregnancy rates following fertility treatment have been
positively correlated with serum AMH levels [1, 4, 11, 12].
This positive correlation has thought to be mainly due to
the increased number of oocytes retrieved during the
treatment rather than oocyte/embryo quality. Our study
confirms these findings. Others have been unable to find a
significant relationship between these two variables
[13, 14]. The results of our study confirm that there is no
significant relationship between serum AMH and embryo
quality. These results are important for counselling women
prior to the start of IVF treatment. Embryo quality may be
dependent on several other known and unknown oocyte
and sperm factors. However, serum AMH, a quantitative
rather than qualitative indicator of ovarian reserve, does
not appear to be associated with embryo quality, although
it does help to decide the dose of gonadotropins to be used
for controlled ovarian stimulation and estimate the number
of oocytes that may be retrieved.
Conclusions
The results of our study show no significant association
between serum AMH and embryo quality in women
undergoing IVF/ICSI treatment when embryo quality was
assessed using the KID scores generated by time-lapse
imaging which is a better method of embryo assessment
rather than conventional morphological assessment.
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